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Abstract
Locoregional treatment is the specific delivery of therapeutics to their desired sites of action
with minimized systemic adverse effects. In this approach, drug is administered through
topical instillation, inhalation, intra-lesional or intra-arterial injection. Decades of experience
in locoregional treatment have delivered meaningful benefits to patients with localized
diseases (e.g., osteoarthritis, ocular disorders and liver cancers). However, improvements are
required for this type of treatment to be more effective. For transarterial chemoembolization
(TACE) therapy of hepatocellular carcinoma (HCC), the most current approaches do not
allow repeat treatment as the drug delivery vehicle is not degradable. In addition, image
contrast agents for visualization are administered separately, leading to uncertainty of the
drug location.
In this thesis, the concept of a multifunctional ‘nano-on-micro’ delivery system was explored
for enhanced TACE therapy. Magnetic hydrogels composed of poly(vinyl alcohol) (PVA)
and iron oxide nanoparticles (IONPs) were prepared and shaped into microparticles using
microfluidics. This system was able to deliver the anti-cancer drug, doxorubicin (DOX), with
co-localized IONPs as a contrast agent to visualize drug location. Degradability of the PVA
hydrogel carrier allows for repeat treatment. To enhance drug loading, we explored the use of
silica nanoparticles (SiNPs) as an effective drug carrier. Loading was investigated using
lysozyme as a model protein and applied to N-94, a therapeutic peptide for dry eye treatment.
The results demonstrated SiNPs system could provide controlled drug release that is also
degradable under simulated physiological conditions. Building on these results, silica (SiO2)
was introduced to prepare PVA-SiO2-IONP microparticles. In addition to all the positive
attributes of the original system, the PVA-SiO2-IONP microbeads have increased drug
loading and tunable release profile.
The concept of a multifunctional ‘nano-on-micro’ delivery system demonstrated for TACE
therapy can be applied to other diseases where locoregional treatment is applicable.
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Summary for Lay Audience
Locoregional therapy is a treatment strategy where therapeutics are delivered to sites of the
diseases via topical instillation, inhalation or injection. This approach can potentially
minimize the involvements of invasive surgery and systemic side effects. Transarterial
chemoembolization (TACE) is a locoregional therapy that is used in the treatment of
hepatocellular carcinoma (HCC), which is commonly known as liver cancer. Microbeads are
used to block tumor blood vessels and to deliver therapeutic drugs to the tumor site. Most of
the beads currently used cannot be removed after the anti-cancer drug is delivered, so repeat
treatment would not be possible. Also, to determine the location of the beads, imaging
contrast agents have to be injected separately to the proximity of beads' delivery site. This
causes uncertainty as to the exact location of the treatment site.
For TACE therapy, we developed a poly(vinyl alcohol) (PVA) hydrogel-based
multifunctional delivery system containing iron oxide nanoparticles (IONPs) and silica
(SiO2) particles that can deliver the drug and the image contrast agent within the same
package. This allows the drug to be delivered effectively. In addition, the microparticles can
be monitored via imaging more precisely. The delivery system is also degradable, which
would allow repeat treatment at the same tumor site. These improvements would lead to
enhanced treatment and better outcomes for the patients.
The concept of a multifunctional delivery system demonstrated for TACE therapy can be
applied to other diseases where locoregional treatment is applicable.
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Chapter 1

1

Introduction

1.1 Background and Motivation
Drug release systems are drug depots that aim to confine the drug's pharmacological
activity to the target site with a predetermined release profile. The ideal formulation
should be able to (1) maintain the local concentration within the therapeutic window, (2)
prolong drug release at the site of disease, (3) protect therapeutics from inactivation or
degradation, (4) produce little or no systemic toxicity, (5) be tailored to the
administration route and physiological features of the desired site of action [1].
Since the first drug-polymer system was introduced in the mid-1960s [2], controlled
delivery technologies have undergone profound advancement over the past 60 years. This
is represented by the move from short-term (1-2 day) delivery formulations in the form of
tablets or ointments, towards long-term (6-12 months) and modulated formulations in
micron or nanoscale dosage forms [3]. The choice of drug carriers also evolves from nondegradable polymers like silicone rubber and ethylene-vinyl acetate to a wide array of
biodegradable polymers. Of note, hydrogels and nanocarriers composed of biodegradable
materials dominated the research landscape in the past decade and have established
promising clinical relevance, and the systems based on nanoparticles are projected to be
leading the research on targeted delivery in the future [3,4].
Existing drug delivery systems can be categorized into two types based on the
administration route and action mechanism. The first group is usually administered via
oral or intravenous route and reaches the desired site of action through blood circulation.
Typical delivery platforms are tablets [5] and nanoscale particles such as polymeric
nanoparticles [6], lipids [7] and micelles [1]. Although controlled release formulations
offered many advantages over the conventional dosage forms, they are suffering from
suboptimal pharmacokinetic profiles or poor stability and low bioavailability [8,9]. The
second group of delivery systems are characterized by wafers, hydrogels, and inhalable or
injectable microparticles [10]. They can be implanted or injected within or adjacent to the
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site of diseases, leading to locoregional drug delivery. Localized treatment regimens can
circumvent hepatic first-pass metabolism and gastrointestinal enzymatic degradation and
bypass different biological barriers, resulting in improved bioavailability [11].
The advancements in controlled release techniques expanded drug delivery options and
fostered safer, more efficient and compliant treatments. In contrast to systemic delivery,
locoregional drug delivery limits the presentation of the drug to a target site for its release
and absorption. Drug administration can be achieved through implantation, injection or
inhalation [10]. This delivery strategy provides a number of advantages over systemic
administration such as minimally invasive administration, lower total drug dosage and
fewer adverse side effects.
Locoregional drug delivery plays a well-defined role in the management of the diseases
with localized nature. It remains one of the main strategies treating osteoarthritis [12],
perturbed wounds [13] and a range of ocular disorders [14]. A wide range of treatment
options is currently in clinical and preclinical investigations, including devices,
macromolecular drugs (e.g., peptides and proteins) and small molecules [12,14,15].
Future research is likely to focus on expanding the drug spectrum, developing long-term
controlled release formulations and addressing the safety concerns.
In addition, locoregional delivery of chemotherapeutics extends treatment options in case
of solid tumors that are easily accessible. Patients undergoing intraductal administration
of liposomal doxorubicin have shown higher drug concentration in the breast than
intravenously injected groups, indicating reduced systemic toxicity [16]. In the case of
ovarian cancer, Lu et al. found that intraperitoneal treatment provided sustained drug
levels in the peritoneal cavity with lower systemic drug exposure [17]. Similarly, in the
postsurgical management of glioblastoma, implantable Gliadel® wafer could provide a
drug concentration up to 1200 times higher than the systemic route with no significant
safety concerns [18,19]. Locoregional treatments have also demonstrated promising
results as the alternative or adjuvant to other forms of treatment in managing lung and
liver tumors [20,21].
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Decades of experience in locoregional drug delivery have delivered meaningful benefits
to an appreciable number of patients and imparted additional requirements for controlled
release systems. First, the retention time of drug depots in the targeted site can be
extended. Delivery systems with mucoadhesive and drug-protecting attributes would be
highly desirable in such circumstances [22]. Second, drug permeation and absorption
should be improved. In this context, drug carriers that are charged, lipophilic and small in
dimension will be of great value [23,24]. In image-guided locoregional delivery like
transarterial embolization (TACE), controlled release systems with CT/MRI detectability
would be highly beneficial [25]. In addition, for the best treatment outcome, co-delivery
systems might be necessary [25,26]. Last but not least, in consideration of
biocompatibility and repeated drug administration, the delivery system should be able to
degrade without forming toxic substances in vivo.
The realization of the desired drug delivery systems relies upon novel material strategies.
The significant progress in nanotechnology and polymer science offers a great
opportunity. It can combine the intrinsic strengths of macroscale systems (e.g.,
hydrogels) with properties (e.g., antimicrobial and imageable) of nanoparticles. This
combinational system allows a multifunctional delivery formulation. A wide range of
nanoparticles such as superparamagnetic iron oxide nanoparticles (SPIONs) [26–28],
silica nanoparticles (SiNPs) [29–31], lipid nanoparticles (LNPs) [32] were successfully
incorporated into hydrogels through physical or chemical interactions. The incorporation
of nanocarriers provides a tool to alter the mechanical strength, drug release and hydrogel
degradation. These manipulations can be done by varying the concentration of nano
components in the gel matrix [30,31,33,34]. Compared with the delivery systems based
on a single platform, combinational systems offer expanded spectrum of loadable drugs
and prolonged drug release [35]. In addition, the nanoparticle-hydrogel interaction adds a
degree of freedom in regulating drug release and polymer degradation [27].
To conclude, locoregional drug delivery has gained increasing importance for treating
disease with localized nature. Drug delivery systems composed of hydrogels and
nanoparticles demonstrate huge potential in fulfilling the stringent requirements placed
on locoregional delivery. As the therapeutics and intervention techniques continue to
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grow, it is expected that novel drug release systems will be in high demand. We believe
the development and optimization of multifunctional drug delivery systems will deepen
the understanding of fundamental science and, more importantly, lead to significant
clinical impact in the coming decades.

1.2 Objectives
In previous work in our laboratory, we explored PVA-iron oxide nanoparticles (IONPs)
nanocomposite hydrogels. We have shown that the incorporation of IONPs contributes to
the crosslinking of the PVA and leads to a ‘degradable’ hydrogel system [27].
The overall objective of this thesis is to explore various formulations to improve and
expand their applications in locoregional drug delivery. To achieve the objectives, a
series of specific goals are set up and listed below.
1. To develop a range of delivery systems in the form of nanoparticles or composite
hydrogels.
2. To characterize the delivery systems in terms of size, morphology, composition,
and magnetic properties.
3. To investigate drug release profiles at different environmental conditions.
4. To study the degradation/dissolution of the drug carriers.
As shown in Figure 1.1, the first stage (Chapter 3) of this thesis is regarded as a
continuation of our prior work. Magnetic PVA-IONP hydrogels were prepared and
shaped into microparticles using microfluidics for doxorubicin delivery with IONPs colocalized for visualization of drug location at the tumor site. Degradability of the carrier
also allows for repeat TACE treatment. In the second stage (Chapter 4), non-porous silica
nanoparticles (SiNPs) were explored as a carrier for bioactive protein and peptide N-94
for the treatment of dry eye disease. Finally, a modified microbeads formulation
composed of silica microparticles, IONP and PVA hydrogel (PVA-SiO2-IONP) was
developed and characterized for doxorubicin delivery. The optimized system
demonstrated an increased drug loading and tunable release profile compared to the
original PVA-IONP system (Chapter 5).
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Figure 1.1 Schematic of the interrelationship of the research work described in
Chapter 3-5.

1.3 Thesis Structure
This thesis is structured into 6 chapters. Chapter 3-5 will describe three projects towards
the development and improvements of locoregional drug delivery systems.
•

Chapter 1 Introduction

This chapter provides a general introduction of locoregional drug delivery and controlled
release delivery systems, as well as the objectives and outline of this thesis.
•

Chapter 2 Literature Review

This chapter gives an in-depth review of the rationales of designing a microparticulate
drug delivery system. Topics including transarterial chemoembolization, dry eye
didsease, design criteria for drug-eluting microparticles, design rationale for
multifunctional materials and droplet microfluidics are comprehensively reviewed.
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•

Chapter 3 Development of Multifunctional PVA-IONP Microparticles for TACE

This chapter introduces the design of PVA-IONP microparticles as potential drug-eluting
beads (DEBs) in TACE treatment. Microparticles were fabricated via microfluidic
technique. The MRI images of microbeads of various concentrations were taken to
examine the contrast enhancement. Doxorubicin loading and release were performed.
Degradation studies were performed in the acidic and physiological pH conditions.
•

Chapter 4 Development of a Multifunctional Bioactive Protein/Peptide Delivery
System for Dry Eye Disease

This chapter describes the work on SiNPs as protein carriers in the application of dry eye
treatment. Adsorption kinetics and isotherm were studied and modelled using lysozyme
as the model protein. The release profile of lysozyme and a bioactive peptide, N-94, were
studied and compared. Dissolution of SiNPs was investigated in a period of one month.
Cell studies were performed to examine the functional equipotency of N-94 to its parent
protein, lacritin, and the biocompatibility of the delivery system.
•

Chapter 5 Development of Multifunctional PVA-SiO2-IONP Microparticles for
TACE

This chapter presents the modification and improvements of PVA-IONP microbeads.
Silica microparticles were introduced into the composite hydrogel. The dependency of
particle diameter on flow rates of the continuous phase and dispersed was explored. The
effect of drug loading, pH and ionic concentration on the drug elution profile were
investigated. The dissolution of PVA-SiO2-IONP microparticles was qualitatively
characterized.
•

Chapter 6 Conclusions and Recommendations

This chapter provides the summary, significance and future directions of the research
presented in Chapter 3-5.
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Chapter 2

2

Literature Review
2.1
Hepatocellular Carcinoma and Transarterial
Chemoembolization

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver
and the third most common cause of cancer-related mortality in the world [1,2]. The
treatment allocation for HCC is dependent on the stage of disease, liver function, and
performance status. Table 2.1 provides an overview of the most commonly used HCC
management guideline- Barcelona Clinic Liver Cancer (BCLC) staging system. With
improved surveillance strategy of patients with cirrhosis and chronic liver disease and
advanced diagnostic methods, more patients are detected at early-stage HCC [3].
Curative treatments, including hepatic resection, liver transplantation, and radiofrequency
ablation (RFA) are recommended for patients diagnosed with early-stage HCC [4]. For
HCC that is not amenable to curative procedures, palliative therapies via TACE or
systematic chemotherapy are offered [5].
Table 2.1 Barcelona Clinic Liver Cancer (BCLC) staging system with treatment
recommendations. Adapted from reference [6].

Transarterial chemoembolization plays multiple roles in the clinical management of
HCC, as summarized in Table 2.2. In accordance with the BCLC guideline, TACE is the
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first-line treatment for patients with intermediate stage HCC (BCLC stage B) [6]. TACE
is used in cases with recurrent HCC after curative treatments [7,8]. TACE has also been
used as a bridge for patients waiting to fulfill criteria for transplantation when donor
becomes available [9,10]. Moreover, TACE represents a valuable component in
multimodal treatments for downsizing large tumors [11].
Table 2.2 Roles of TACE in the management of HCC.
Palliative treatment for intermediate stage HCC (BCLC stage B)
Treatment/prevention tool for recurrent HCC after curative treatments by surgery or ablation
Bridging or downstaging tool to liver transplantation
Neoadjuvant therapy to downsize tumor prior to liver resection
Combined therapy with other interventional treatments

The principle of TACE revolves around the dual blood supply of the liver. The normal
tissue of the liver receives most (75%-85%) of its blood supply from the portal vein and
receives the remaining from the hepatic artery. On the other hand, liver tumors receive
~90% of their blood supply from the hepatic artery [5]. It has been reported that the
embolization via hepatic arteries would have minimal ischemic damage on normal
hepatic parenchyma, as its dominant blood supply from a portal vein is unaffected [12].
In addition, unlike oral or intravenous delivery, the chemotherapeutic effect of the drugs
is reserved as this approach bypasses the first-pass metabolism [13].
The success of the TACE procedure heavily relies on imaging techniques and requires a
multidisciplinary tumor board consist of a surgeon, clinical oncologist and interventional
radiologist [14]. In a typical TACE therapy, pre-treatment imaging consisting of a
multiphasic computed tomography (CT) or dynamic contrast-enhanced magnetic
resonance imaging (MRI) of the liver must be obtained preferably within four weeks of
the planned TACE intervention [15]. The pre-treatment imaging aims to acquire anatomic
information to aid in planning the procedure [15,16]. Figure 2.1 schematically describes
the TACE procedure. During a TACE, patients will be given a local anesthetic. The
interventional radiologist places a catheter into the patient's femoral artery and moves the
catheter up until it reaches the hepatic artery in the liver. Three-dimensional vascular
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images (angiogram) are necessary to identify the appropriate tumor-feeding branches. An
X-ray is taken by infusing radio-opaque contrast agents through the catheter. Drugs/drug
carriers and embolic materials are delivered separately or simultaneously depending on
the techniques and delivery systems. The injection is stopped when the stasis flow of
contrast agents existed. Angiography is repeated, and embolization is continued until all
blushed tumors disappeared [17]. In post-procedure care, CT scans are performed to
determine tumor response recurrence 4-8 weeks after the procedure. Sequential TACE
procedures can be performed in 4-16 weeks if any recurrent tumor is identified [12].

Figure 2.1 Schematic demonstration of TACE. Figure reprinted with permission
from [18].
TACE can be classified as conventional TACE (cTACE) and drug eluting beads (DEB)TACE. The cTACE involves an arterial infusion of an emulsion containing
chemotherapeutics in iodinated oil (Lipiodol®) followed by injection of embolic agents to
occlude the same tumor vasculature. A major advantage of cTACE is its radiopaque
iodinated oil allows intra-procedure visualization of the drugs, which is helpful to
optimize the imaging guidance. The drawbacks of cTACE include the rapid release of
drug from Lipiodol associated with the weak bonding between the doxorubicin and the
carriers [19]. Other drawbacks underline the unstable and unpredictable post-treatment
outcomes, which might be due to the variants in the procedure, as cTACE is not a wellstandardized procedure and can be largely dependent on the medical specialists'
experience, treatment devices available and the therapeutic agents injected [20].
The limitations of cTACE led to its gradual replacement by DEB-TACE. DEB-TACE
takes advantage of drug-impregnated microspheres and allows the simultaneous delivery
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of chemotherapeutic agents together with vessel occlusion. The DEBs essentially serve as
a drug carrier, contrast agent and embolic agent. The integration of multiple functions is
achieved by the appropriate design of the size and composition of the matrix. DEBs are
typically in the diameter of 40-900 𝜇m, making them large enough for vascular
embolization [21]. Drug loading is performed prior to the TACE procedure by immersion
methods and typically takes 20 min to 2 h to complete depending on the bead size and
materials [22,23]. The loading is driven by ionic interactions between the drug molecules
with polymeric backbone. The contrast medium could be incorporated by physical
mixing with DEBs [24,25] or via covalent coupling with the polymeric backbone [26].
Imageable DEBs can also be prepared by entrapment of iron oxide nanoparticles (IONPs)
[27–29]. Of note, DEB-TACE is performed in a more standardized way as compared to
cTACE, both during preparation and administration. The standardization leads to more
homogenous and stable patient data [30]. In some clinical studies, DEB-TACE has shown
improved tolerability, better tumor response and lower systemic toxicity than cTACE
[31,32].

2.2

Dry Eye Disease and Treatments

Dry eye disease (DED) is a multifactorial disease of the tear and ocular surface,
characterized by hyperosmolarity, tear film instability, ocular surface inflammation, and
visual discomfort [33]. These changes in tear composition activate stress signaling
pathways in the ocular surface epithelium and resident immune cells, which triggers the
production of inflammatory mediators to recruit and activate immune cells and produce
cytokines, such as interleukin (IL)-1𝛽, IL-6, and tumor necrosis factor (TNF)-𝛼 [34]. The
secretion of cytokines would initiate a vicious cycle and further damage the cornea and
lacrimal glands, decline the tear function and worse the symptoms [34,35].
The current DED treatments focus on minimizing the inflammation and supplementing
the tear film components [36]. The topical application of lubricating agents, antiinflammatory therapeutics, biological tear components through eye drops remains the
commonest intervention option for patients with dry eye [37]. For this treatment, punctal
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plug insertion is encouraged to prolong the resident time of aqueous and artificial tears on
the ocular surface [38].
The topical administration is often associated with two challenges: the low ocular
bioavailability of the drug and the unfavorable long-term use of the commonly prescribed
therapeutics [36,37]. Less than 5% of topically applied drug doses can reach deeper
ocular tissues due to the complex anatomical and physiological barriers of eyes [39].
Reflex tearing, blinking, nasolachrymal drainage and metabolic degradation impede
sufficient time residence and deep drug permeation [40]. As a result, frequent dosing of
the drugs at high concentrations is required to deliver sufficient therapeutic effects. The
poor patient adherence and high drug dosage could result in extreme fluctuations in drug
ocular concentrations and systemic drug distribution, leading to undesirable side effects
[37].
To prolong the ocular residence time of the therapeutics and minimize the oscillations in
the drug concentrations, numerous drug delivery systems have been developed.
Nanomicelles, nanoparticles, liposomes, and hydrogels were loaded with drugs and can
provide an effective drug concentration in the eye for a week [41]. In addition to being
used solely, such systems could be included in other devices such as contact lens. The
liposome-laden lens have demonstrated a controlled drug release over a period of 8 days
[40].
The potential risks associated with the long-term use of commonly prescribed drugs
posed a challenge for DED treatment via topical route. Steroids are one of the most
effective and rapid medications for DED. However, prolonged use is not recommended
due to the risks of developing an ocular infection, glaucoma, and cataract [42]. Topical
instillation of cyclosporine can lead to complications such as lid maceration and corneal
epitheliopathy [43]. Another alternative treatment is lifitegrast, the only U.S. Food and
Drug Administration (FDA)-approved drug for both signs and symptoms of DED [44].
The adverse events consist of ocular irritation and hyperthermia. Systemic effects are
headaches, erythema, and musculoskeletal pain. Clinical studies on long-term safety
profiles are still quite limited and represent an essential avenue for future investigation.
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The adverse ocular events associated with commonly prescribed molecules have
encouraged research and development of biotherapeutics as alternatives. Among them,
bioactive tear proteins have emerged as promising candidates.
Lacritin is a growth-factor-like tear protein (~ 25 kDa) that is selectively downregulated
in dry eye [45,46]. It is produced by human lacrimal acinar cells, corneal, conjunctival,
and salivary epithelia [47]. Lacritin has demonstrated mitogenic and cytoprotective
properties on human corneal epithelial cells (HCECs) and can promote basal tearing that
is sustained for at least 4 hours when topically instilled in rabbits [46–48]. It was found
that lacritin’s C-terminal is mitogenic and has a amphipathic 𝛼-helical structure [49]. In
addition, its C terminus targets cell surface syndecan-1 (SDC1), a transmembrane protein
that regulates mitogenic signaling, making lacritin a potential cell-targeting strategy for
DED.
Various C-terminal fragments of lacritin have been produced via chemical synthesis. For
example, N-65 represents a lacritin truncation mutant lacking 65 N-terminal amino acids
[50]. Other lacritin peptides such as N-55, N-74, N-94, and N-104 were synthesized, as
described elsewhere [51]. The synthetic surrogates have demonstrated antimicrobial
properties and they are effective in stabilizing the tear lipid layer and maintaining
epithelial homeostasis [52].
The combinational use of protein-based therapeutic agents with drug delivery systems
offers a promising tool to treat DED. The topical administration of lacritin molecules or
its fragments may contribute to a restored team film microenvironment, particularly
under dry eye conditions where they are deficient [47]. As biomolecules are prone to
decomposition on the inflammatory and oxidative ocular surface, the use of drug delivery
systems, in return, can potentially protect and allow sustained availability of protein
therapeutics [53].
For dry eye treatment, future efforts should be dedicated to discovering safer drug
molecules and more effective delivery options. The replacement of steroid therapy with
natural tear components can provide a long-term solution by physiologically rescuing the
ocular surface without provoking any noticeable adverse effects. On the other hand, the
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advancement in carrier systems is expected to facilitate the delivery of drugs, concentrate
drugs at the target site, and prolong their corneal residence time, ultimately reducing dose
and dosing frequency.

2.3

Chemotherapeutic Agents

For TACE, the most common sole-agent anticancer drugs used are the anthracycline
group. In published cohort and randomized studies, anthracycline antibiotic doxorubicin
(DOX) takes up 36% of the cases while epirubicin represents 12% of the records. Other
popular chemotherapy agents include cisplatin (31% of the cases), mitoxantrone (8%),
mitomycin (8%), and poly(stylene-co-maleic acid)-conjugated neocarzinostatin
(SMANCS, 5%) [54]. The chemical formula and structure of commonly used anticancer
drugs are shown in Table 2.3. Notably, the criteria to decide the dosing regimen is not
standardized: some physicians prefer to determine it based on patient’s body surface area,
weight, tumor burden or bilirubin level, while others prefer to use a fixed dose [55]. The
usual dose for DOX is 40-100 mg while cisplatin between 50-100 mg [14,15]. Some
randomized clinical studies showed no significant differences in survival rate between the
single-drug treatment of DOX and cisplatin or epirubicin [56–59]. Moreover, to date,
there is no evidence of the superiority of any single cytotoxic anticancer drug over other
drugs or for mono-drug chemotherapy versus combination chemotherapy [14,15].
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Table 2.3 Summary of commonly used cytotoxic anticancer drugs for TACE.

While the dosing regimen is not standardized, the EASL-EORTC [(European Association
for the Study of the Liver) or (Response Evaluation Criteria in Solid Tumors)] clinical
practice guidelines provide a general rule for the dose of DOX. The recommended DOX
dose per treatment is 50-75 mg to a maximum value of 150 mg (75 mg/m2 body surface
area) [60]. Patients may receive 3- 4 TACE treatments within six months, with each
session being ~3 to 4 weeks apart. The maximum recommended lifetime dose of DOX is
900 mg (450 mg/m2), in correlation to the cardiac toxicity when the drug is administered
systemically [61].

2.4
Drug-eluting Microparticles and Commercial
Products
Over the previous decades, several DEBs have become commercially available (Table
2.4). The most commonly used microparticles in clinical practice are DC BeadTM/LC
BeadTM (Biocompatibles, United Kingdom), the radio-opaque version of DC Bead: DC
Bead LUMITM (Bosten Scientific, United States), HepaSphereTM/QuadrasphereTM
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(BioSphere Medical, France), OncozeneTM/Embozene TANDEMTM (Varian Medical
Systems, United States), and LifePearl® (Terumo International Systems, Belgium).
Commercial DEBs are typically offered in a size range (e.g., 70-150 μm, 100-300 μm,
300-500 μm, 500-700 μm). The most common bead sizes are 100-300 μm, 300-500 μm
and 500-700 μm [62], while DEBs in 100-300 μm provide the a better treatment response
and fewer major complications than beads with larger diameters [63,64].
Table 2.4 Overview of commercially available DEBs.

Y: yes, N: no.

Commercial DEBs carry negative charges and allow the loading of chemodrugs with
counter ions (e.g., DOX, epirubicin and cisplatin). DC BeadTM is made of PVA
functionalized with sulfonate groups on the bead surface [65]. DC BeadTM microparticles
are usually packaged in 2 mL vials at a hydrated state in a sodium phosphate solution and
provide a DOX loading capacity of up to 45 mg/mL [64,65]. DC Bead LUMITM is
derived from DC BeadTM and the PVA backbone is covalently bonded with imaging
moieties iodine, therefore allows standard fluoroscopy and CT imaging [66].
HepaSphereTM is a poly(vinyl alcohol-co-acrylic acid) microsphere packaged in a dry
state. This type of beads expands to four times in volume upon exposure to saline. The
presence of carboxylate groups allows binding of positively charged drugs throughout the
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beads and can achieve a DOX loading ~40 mg/mL beads [22]. Likewise, TANDEMTM is
composed of poly(methylacrylic acid) microspheres with perfluorinated coating. The
pendant carboxylate groups allow up to 50 mg/ml loading of DOX [67,68]. LifePearl®
beads consist of a poly(ethylene glycol) (PEG) modified with sulfonate groups and can
provide a DOX loading at ~37.5 mg/ml [69].
The in vitro drug loading and eluting profile provide helpful information to determine the
dosing regimen and predict the pharmacokinetics of the drugs. Baere et al. conducted a
comparative study of the four DEBs (DC BeadTM, HepaSphereTM, Embozene TANDEM
TM

and LifePearl®) [22]. All four types of DEBs can reach maximum loading in ~ 2 h,

with larger particles generally take a longer time to reach the plateau. The drug elution
profile was examined under sink condition in flow cells, all four types of DEBs exhibited
incomplete drug release, and the maximum release achieved within 5 hours. The results
also showed a decline in eluted DOX, indicating degradation and adsorption of DOX at
neutral pH [70].
The future direction in DEBs is in the development of size-tunable, imageable,
degradable beads. DEBs that are in support of combination treatments is another research
focus. The design criteria and rationales for DEBs will be discussed in detail in the
following section.

2.5

Design Criteria for Drug-eluting Microparticles

Multiple parameters that could significantly affect the clinical benefits of DEB-TACE.
The morphological characteristics can affect the vascular distribution and occlusive
behavior of the microparticles. Imageability/detectability is useful in guiding the
intervention. More importantly, the co-localization of contrast agent with drug allows a
more precise tracking of drug distribution relative to the position of the tumor.
Targetability allows tumor-specific delivery through magnetic resonance navigation
(MRN), potentially minimizing the unwanted toxicity to healthy tissue. Advantages of
controlled release formulations include an effective drug concentration in tumor tissue
and reduction of systemic exposure. The purpose of having degradable DEBs is to
prevent tumor hypoxia and allow repeated interventions. Moreover, the ability to deliver
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multiple therapeutics is desired as it could enable comprehensive and multimodal
therapies for certain cancer patients. A multifunctional delivery system, as its name
suggests, can exert multiple functions with one platform. Such system is highly
advantageous for the locoregional treatment of complex diseases, such as cancer. In this
section, the design considerations for multifunctional drug-eluting microparticles are
rationally discussed.

2.5.1

Shape

The shape of DEBs has a significant impact on the efficacy and safety of the TACE
treatment. Non-spherical poly(vinyl alcohol) (PVA) particles emerged in the 1970s as a
permanent embolic option complementing degradable gelatin sponge. It was marketed as
Ivalon® and distributed as a sheet or block form. For each use, PVA particles were
manually produced by a sawblade or a rotating rasp. And the shavings were subsequently
filtered with sieves and sorted into particles of different sizes [71]. The resulting PVA
particles are irregular in shape due to the preparation method. This led to two issues: (1)
the actual size does not coincide with the dimension provided by the vendor and (2) the
tendency for aggregation. Derdeyn et al. [72] studied the size of PVA particles and found
that many were larger than the advertised minimum size. This could mislead the
radiologist in selecting the agent compatible with the dimension of vessels to be
occluded. In addition, the PVA particles possessed a huge size deviation. The oblong
particles may have an extremely short axis (< 20 μm) or sharp fragments. Such fractions
could cause off-target embolization or end-organ damage [73]. The irregular surface and
broad size distribution also led to clumps that made catheter administration very difficult.
In addition, this tendency to form aggregates resulted in a larger effective size, which
contributed to a more proximal rather than distal occlusion [74]. Nevertheless, particulate
non-spherical PVA holds its utility in widespread scenarios where proximal occlusion is
desired, such as in embolizing uterine fibroid, managing epistaxis, treating solid organ
bleeding [75,76]. In situations where deeper tissue penetration is required, spherical
particles would be the more suitable option.
The clinical disadvantages of irregular-shaped PVA particles prompted the development
of calibrated microspheres. During the past three decades, a number of commercial
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products have become available. Depending on the purpose of the application,
commercial products can be classified into two categories: bland embolic agents (e.g.,
Contour SETM, Embosphere® and Bead Block®) and embolic DEBs (e.g., DC/LC
BeadTM, HepaSphere/QuadraSphereTM, Embozene TANDEMTM and LifePearl®).
Microspheres with calibrated sizes have demonstrated improved distal penetration and
physiologic outcomes than non-spherical PVA particles, hence becoming a preferred
choice for physicians [77–79].

2.5.2

Size and Size Distribution

Size and size distribution are critical in determining flow behavior and physiologic
outcome of the DEB-TACE treatments. Smaller particles tend to penetrate deeper into the
vasculature and reach more distal locations [78,80]. Regarding the size distribution, most
commercial products are offered in a size range (e.g., 70-150 μm, 100-300 μm, and 300500 μm) rather than in one size. A broad size range did not render significant targeting
disadvantages over a narrow one. In a comparative study conducted by Laurent et al.,
microspheres with a broader size distribution demonstrated similar vasculature
distribution in animal models as compared to narrow microparticles [81]. This study
suggests that microparticles with a broad size range might provide the same level of
vessel embolization as unisize beads.
Moreover, the size and shape of DEBs play a critical role in regulating the drug-eluting
profile. Smaller DEBs provide faster release than larger ones due to the greater surfaceto-volume ratio [82]. In addition, irregular-shaped DEBs produced a faster drug release
rate compared to microspheres. This might be associated with a larger surface area
[83,84]. As such, the geometrical factors of DEBs must be considered in the development
of DEBs to achieve the desired embolization and drug delivery outcome.

2.5.3

Imageability/Detectability

As stated in section 2.1, vascular imaging plays an integral role in TACE by providing
intra-procedural guidance for catheters, confirming complete occlusion, and postprocedural monitoring on beads distribution and tumor progression [85,86]. DEBs with
intrinsic CT and (or) magnetic resonance imaging (MRI) detectability, in this regard, can

22

possibly be used as an indicator of drug/bead distribution and fulfil the imaging needs
without multiple usages of toxic contrast agents. Imageable drug delivery systems were
initially prepared by mixing radiopaque Lipiodol emulsions with the drug. However,
animal studies revealed the discordance between the contrast and drug. More specifically,
the spatial distribution of contrast agents did not correlate with the distribution of the
drug. This could be due to the instability of the formulation and rapid passage of the drug
to the systemic circulation after administration, as the bonding between the Lipiodol
emulsion and the drug is relatively weak [5,30,87].
DEBs with integrated contrast agents are therefore highly sought-after in clinical practice.
Since the chemotherapeutics and contrast components are held together, the location of
DEBs represents the exact drug location. In addition, the intensity of the signal can be an
indicator of local drug concentration. The most common approach to constructing an
imageable DEB system is by incorporating magnetic nanoparticles (NPs) into the
hydrogel matrix. The generation of large magnetic dipoles thereby local magnetic field
gradient within the NPs will strongly alter the relaxation times of surrounding water
protons, resulting an enhanced imaging contrast [88]. Commonly used magnetic NPs are
superparamagnetic iron oxide nanoparticles (SPIONs), tantalum NPs, cobalt NPs, and
lanthanide moieties [89].

2.5.4

Targetability

Targeted drug delivery represents another future direction for locoregional therapy, and
this can be achieved by magnetic targeting. In this approach, magnetic particles are
embedded in the drug carriers to localize the drugs at the site of action. The drug-carrier
complex is first injected intra-arterially. High-gradient, external magnetic fields
generated by rare earth permanent magnets are used to maneuver magnetic particles to
achieve an exclusive drug accumulation at the tumor site [90]. The magnetic carriers
contain SPIONs have demonstrated improved tumor suppressive behaviors in treating
brain [91,92], lung [93] and bone cancers [94]. The limitations with magnetic targeting
are that the gradient-induced forces decline rapidly with the distance from the magnet,
and it is also difficult to tailor the shape of the gradient field to the anatomy. These
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drawbacks limit the application of magnetic targeting to superficial tumors or small
animals.
Magnetic resonance navigation (MRN), also referred to as magnetic resonance targeting
(MRT), has been developed to overcome the weakness of magnetic targeting. Clinical
MRI coils are explored as the source of steering (propelling) force. The distance from the
magnet is no longer a restraint as MRI gradient coils can offer constant amplitude over
depth as distant as 50 cm [95]. The physical principle behind MRT is to use the three
orthogonal gradient coils inside the MRI bore to induce a 3D directional magnetic force
to propel the magnetic particles along a predefined trajectory [96]. The majority of the
state-of-art facilities use MRI machines with a magnetic field strength of 1.5 or 3T [97].
The clinical magnets (≥1.5 T) are considered to be sufficient for saturating the
ferromagnetic materials throughout the body so a maximum magnetic force/response
could be exerted on the particles [96,98].
A significant challenge with MRN is that the magnetic gradient amplitudes are
insufficient for navigating smaller particles. For navigation purposes, MRI gradient coils
need to generate a propelling force that could overcome the drag force. The magnetic
force increases at a cubic power with the particle radius (proportional to the volume),
while drag force increases in a linear fashion in laminar flow (e.g., small arteries,
arterioles or capillaries) [96,99]. This suggests that larger millimeter particles can be
navigated more efficiently than smaller particles. Additional gradient coils (also referred
to as steering coils) could be installed in the MRI bore to acquire stronger magnetic
gradients to navigate smaller particles. Upgraded gradient coils could strengthen the
magnetic gradients of a 1.5-T clinical scanner from 40 mT/m to up to 400 mT/m [95].
The configurational modification allowed efficient steering of microparticles with a
diameter of 11 𝜇m in a y-shaped microfluidic channel.
As the SPIONs inside the DEBs can also serve as the contrast agents to guide the
delivery, simultaneous steering and imaging are possible with a tailored MRI pulse
sequence. Felfoul et al. designed an MRI pulse sequence that reserved 90% of the
maximum propelling force that can be applied while imaging [100]. The author
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demonstrated simultaneous steering and tracking of millimeter particles using a vascular
network phantom. However, this study was lack of clinical relevance as it was conducted
in the absence of flowing fluid. Further research should include the simulation of
physiological fluids and tests on animal models to examine the clinical viability of the
combination of steering and imaging.
In summary, the validity and efficacy of MRN have been demonstrated in vitro and in
vivo. MRN provides a promising approach to deliver drugs in a non-invasive and highly
targeted fashion. In imaging arena, coil configuration, control scheme, and pulse
sequence must be upgraded for clinical use. In the realm of material science, efforts could
be made in finding the suitable type and combination of polymers and magnetic
components to ensure both imageability and targetability.

2.5.5

Controlled Release

The drug release profile has huge impact on clinical outcome of TACE. Due to the weak
association between the drug and oil, Lipiodol emulsions render rapid drug release in vivo
and quickly elevate plasma drug concentration. This burst release could lead to postembolization syndrome and inadequate treatments [101,102].
In contrast, DEBs allow controlled drug release mainly through two mechanisms: (1) ion
exchange between the positively charged drug and the same charge ions in the release
medium and (2) diffusion of the drug through the polymeric network and into the release
medium. Commercial DEBs including DC BeadTM, HepaSphereTM, Embozene
TANDEMTM and LifePearl® are made of the ionic polymeric matrix, and the drug release
typically follows the first mechanism [103]. The second release mechanism is prevalent
in DEBs composed of non-ionic polymers, such as poly(vinyl alcohol) [104]. For drug
delivery systems consisted of degradable polymers (e.g., PLGA and chitosan), other
mechanisms such as erosion/ degradation of the matrix cohabits with the diffusion and
can dominate over diffusion in many cases [105,106].
DEBs with controlled release functions could improve safety and efficacy of TACE
through maintaining the drug concentration in tumor tissue within a therapeutic range and
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lowering its levels in the systemic circulation. In a phase II clinical trial, DEB-TACE
group significantly decreased the drug-related systemic and liver toxicity versus the
cTACE group. In addition, the response rate and disease control rate was higher in the
DEB-TACE group [31].

2.5.6

Degradability

As suggested by Ha et al., TACE was performed every 6-8 weeks to eradicate tumors
until thromboses and/or metastases were developed or patients cannot tolerate more
hepatic damage [107]. Degradable DEBs could be beneficial in TACE to (1) prevent
extended periods of tumor hypoxia, as it can stimulate the expression of vascular
endothelial growth factor (VEGF), which adversely promote tumor growth [108], and to
(2) allow repeat treatments.
Over the past decade, numerous multifunctional DEBs composed of degradable materials
were explored (Table 2.5). Such systems are typically composed of hydrogel matrix with
cleavable linkers that can disintegrate in the presence of acidic hydrolysis, enzyme or
reactive oxygen species (ROS) environment in vivo [109]. Future work could be
dedicated to the study of degradation rate, degradation products and the effect of
degradation on angiogenesis.
Table 2.5 Overview of the degradable drug-eluting microparticles.
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a

encapsulation efficiency (%) =

actual amount of DOX in microspheres
mass of feed drug

× 100%

DOX: Doxorubicin, CMs: chitosan microspheres, ACMs: acetylated CMs, PLGA poly(lactide-coglycolide) (PLGA), MSs: microspheres, PEG: poly(ethylene glycol), PEGMA: poly(ethylene glycol)
methacrylate, N/A: not available.

2.5.7

Delivery of Multiple Therapeutics

The co-delivery of multiple therapeutics with complementary modes of action represents
another future direction for DEBs. TACE leaves the chemotherapy-damaged HCC cells
under hypoxic conditions, transforming the cancer cells into a more aggressive phenotype
[110]. Studies have demonstrated the embolization stimulated the expression of VEGF
that will promote angiogenesis [111]. Systemic administration of antiangiogenic drugs
such as thalidomide [111], vandetanib [112] and sorafenib/sunitinib (both are antitumoral
and anti-angiogenetic) [113,114] combined with TACE have demonstrated satisfying
angiogenesis-suppressing effects in animal models. It is therefore logical to
locoregionally co-deliver these drugs with anti-tumor agents using DEBs [115]. Forster et
al. loaded DC BeadTM with several drug combinations and compared their treatment
safety and efficacy [116]. The co-delivery of two drugs displayed synergistic activity and
reduced cellular toxicity versus the single-drug loaded DEBs. Other types of therapeutics
such as anti-inflammatory agents (e.g., ibuprofen) can be considered as they may reduce
post-embolization inflammation and pain [117].

2.6
Design of Multifunctional Materials for Drug
Delivery
Science, technology and medicine are continuously looking for new and improved
treatments for diseases, which tremendously catalyzed research on less toxic, effective
and cost-effective drug delivery options [118]. The mixing of known materials:
nanoparticles and hydrogels, offers a simple and effective material strategy to address the
clinical needs.
The structural combination of nanoparticles with hydrogels creates a composite platform,
often referred to as nanocomposite hydrogel or nanoparticle-hydrogel composite [119].
Such material bears great potential to integrate the desirable properties of both
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components (i.e., nanoparticle and hydrogel) into a single system and enable additional
functions through the nanoparticle-hydrogel interactions [120].
Nanocomposite hydrogels can be prepared through four main routes. For the first route,
nanoparticles are entrapped in the polymeric network by the gelation of hydrogel
monomers in the presence of preformed NPs [119]. Alternatively, the incorporation of
NPs can be accomplished after hydrogel gelation by allowing the polymeric network to
swell and ‘breathe in’ the suspended NPs [121]. Moreover, the NPs could be introduced
into the gel matrix by loading the hydrogels with the metallic nanoparticle precursors,
followed by a reduction reaction to form metal NPs [122,123]. Another approach to
prepare nanocomposite hydrogels is to use NPs as hydrogel crosslinkers (referred to as
the grafting-onto method in section 2.7.2). Depending on the end groups, the particles are
anchored in the hydrogels through covalent or non-covalent bonds (e.g., ionic or
coordination interactions) with the polymeric chains [124,125].
The properties of the nanocomposite hydrogels are dependent on the innate properties of
the individual components and particle-hydrogel interactions. As shown in Figure 2.2,
commonly used nanoparticles and hydrogels with their desirable properties are listed.
Nanoparticles can bring many unique functions: magnetic responsiveness [99], diagnostic
imaging [126], electrical conductivity [127], antimicrobial activity [128], and
compatibility with both hydrophilic and hydrophobic drugs [129]. Hydrogels are known
for their stimuli-responsive [130], mechanical toughness [131], bioadhesive [132,133]
and controlled release properties [130]. To satisfy the application requirements, the
materials and the preparation methods must be carefully selected.
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Figure 2.2 Design and processing of a multifunctional hydrogel system for
biomedical applications.
The structural and dimensional diversity between the nanocomponents and hydrogels
provide an effective strategy for the independent delivery of one or more drugs. A
composite system containing PLGA nanoparticles and hyaluronan (HA)/methylcellulose
(MC) hydrogel allowed fast drug release from the hydrogel while slow release from the
nanocarriers [134]. This unique feature was adopted by Zhao et al. to deliver two types of
drugs independently [135]. The authors achieved dual drug delivery by formulating PTXloaded PLGA NPs into temozolomide (TMZ)-loaded hydrogel. The co-delivery of PTX
and TMZ resulted in a synergistic effect on glioblastoma cells. In addition to loading one
drug in hydrogel while the other in nanocarriers, an independent delivery can be achieved
by incorporating distinct drug-loaded carriers. For example, Patel et al. prepared
curcumin-encapsulated poly(L-lysine-b-L-phenylalanine) micelles and amphotericin Bencapsulated poly(L-glutamic acid-b-L-phenylalanine) micelles, separately [136].
Hydrogel matrix was created by cross-linking the pendant groups of the polypeptides
using genipin as a crosslinker. The different pH responsiveness of the two nanocarriers
permitted independent and switchable release of the corresponding drug. The drug release
rate can also be tuned by varying the dosage of genipin. The realization of dual drug
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delivery might be helpful in post-surgical cancer management or wound healing, as it
may provide a synergistic effect.
The constitution of nanocomposite hydrogels can potentially address the challenges in
which the nanoparticles or hydrogels are used alone. For example, the incorporation of
lipophilic nanocarriers can potentially address the incompatibility of hydrogels with
hydrophobic therapeutics. In turn, the presence of hydrogel can prolong the drug release
from nanoparticles. Yu et al. utilized lipid nanocarriers to encapsulate a hydrophobic
drug, quercetin, and reached an encapsulation efficiency greater than 97% [137]. The
drug-loaded nanoparticles were then physically embedded in a mixture of carboxymethyl
chitosan (CMCS) and Pluronic® F-127. The resulting delivery system provided a slower
release rate than that of drug-lipid nanoparticles in the absence of hydrogel. This was
believed to be contributed by the three-dimensional and water-dense polymeric network,
which imposed a longer diffusion path and additional diffusion barrier to drug molecules
[138]. In a comparative study, drug release was performed on two formulations:
kartogenin (KGN)-loaded halloysite nanotubes (HNT) and KGN-HNT embedded in
laponite (Lap) hydrogel (KGN-HNT-Lap) [139]. The release kinetics showed that the
composite formulation greatly prolonged the KGN release compared with KGN-HNT
system. The authors substantiated that the hydrogel could act as an inert medium to slow
down KGN release.
In addition, the nanoparticle and polymeric network interactions can render the composite
material with unique properties that are not found in individual components. For
example, Bannerman et al. developed a composite hydrogel comprised of IONPs and
PVA [140]. The biostable PVA developed degradation behavior under an acidic and ironchelating environment. It was believed that the IONPs participated in the cross-linking of
PVA. As a result, the gradual removal of IONPs would weaken the PVA matrix and
allowed the degradation to occur. Nasajpour and coworkers fabricated a microfibrous
membrane of zinc oxide (ZnO) NPs in PCL [141]. It was found that the composite
membranes degraded faster than plain PCL membranes (pH 7.4 and 8.5). The authors
believed that the incorporation of ZnO NPs created cavities within the polymer matrix,
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which may facilitate water diffusion into the PCL. Moreover, the hydrophilic nature of
ZnO NPs may also play a role in promoting PCL-water interaction [141].
Taken together, the combination of nanoparticles with hydrogels provides a
multifunctional platform for drug delivery applications. Such platform endows function
integration from each component and can potentially overcome the limitations of
nanoparticle and hydrogel systems when they are used independently. Moreover, it
provides an additional degree of freedom in designing or tailoring delivery systems
through nanoparticle-polymer interactions.
With the employment of different material processing techniques, the biomedical
application of nanocomposite hydrogels has gone far beyond what a macroscopic system
can reach (Figure 2.2). Electrospraying [142], electrospinning [143], microfluidics [144]
and 3D printing [145] have been used to produce drug delivery systems in the forms of
fiber, microbead and scaffold. The diversity in the geometry could even expand the
application spectrum of nanocomposite hydrogels into regenerative medicine and
multimodal cancer treatments [146–148].

2.7
2.7.1

Choice of Materials and Proposed Systems
Poly(vinyl alcohol)

Poly(vinyl alcohol) (PVA) is one of the most commercially important water-soluble
thermoplastics in use. It has widespread pharmaceutical and biomedical applications,
including drug carriers, scaffolds, wound dressing, contact lens and orthopedic implants
[149].
PVA must be stabilized by crosslinking to form a hydrogel before many of its
applications in biomedical research. Hydrogels are regarded as hydrophilic, crosslinked
polymeric networks that are able to imbibe larger amounts of fluids and swell when
placed in water or biological fluids without losing their structure [150]. The crosslinking
strategies for PVA can be classified as physical and chemical crosslinking.
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Chemical crosslinking use crosslinkers to form covalent bonds between PVA's secondary
hydroxyl groups. Commonly used crosslinkers are monoaldehydes (e.g., acetaldehyde
and formaldehyde), bifunctional aldehydes (e.g., glutaraldehyde and glyoxal)[151] and
dicarboxylic acids (e.g., citric acid and maleic acid) [152,153]. The hydroxyl groups of
PVA react with the crosslinking agents to form intermolecular acetal bridges (bonds)
where crosslinking could occur [154]. In addition to crosslinkers, sulfuric acid, acetic
acid or methanol must be used to form the acetal bridges. PVA hydrogel formed by
chemical crosslinking always retains toxic crosslinkers, which could result in unwanted
biological effects. The residue of initiators, stabilizers and chain transfer agents could
also hinder the in vivo application of PVA [155].
High energy irradiation offers an alternative approach to prepare chemically crosslinked
PVA. During this process, electron beam or 𝛾 irradiation is used to generate free radicals
on the polymeric chain. The radicals would subsequently combine through covalent
bonds to form a crosslinked network. The advantages of this strategy are: no crosslinkers
are required; no residual impurities; the degree of crosslinking and the pore size of PVA
gels are tunable by radiation dose and concentration of the polymer solution [156]. The
limitation with this method is that the radiation exposure may damage the bioactive
payloads if the crosslinking is performed after the loading [157].
Physically crosslinked PVA prepared by freezing-thawing technique has generated
significant interest in biomedical research due to the avoidance of toxic crosslinking
agents and impurities. In a typical preparation, a homogenous PVA solution is placed
under repeated freezing and thawing cycles. The gel obtained from such cryogenic
treatment is often referred to as a cryogel [158]. Phase separation and crystallization are
the major mechanisms for cryogel formation and impact independently during the freezethaw cycles [159]. The formation of the crosslinked microstructure consists of multiple
stages. During the freezing process, ice crystals formed within the homogenous PVA
solution. The water volume expansion and phase separation expel PVA into close contact
with each other and result in the formation of polymer-rich regions and polymer-poor
regions. In the polymer-rich regions, PVA chains come into close contact with each
other, facilitating the intra- and intermolecular interaction through hydrogen bonding
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[159,160]. Repeated freezing processes allow polymer chains to fold into highly
structured crystallites in PVA-rich regions as network junctions. In thawing stages, ice
crystals melt, leaving water-filled micrometer-sized pores that make up the polymer-poor
regions [158].
A number of process parameters in the preparation could be used to tailor the structure
and properties of PVA cryogels. These parameters include but are not limited to
temperature limits of thermal cycling, number of freezing-thawing cycles, polymer
concentration in the solution and molecular weight of PVA [161]. These parameters
affect the properties through chain mobility and intermolecular hydrogen bonding,
resulting in variations in the size and number of crystallites. PVA cryogels with more
crystalline structures (higher crystallinity) generally display a smaller porosity and higher
rigidity [155,158].
Among all the characteristics, the diffusivity of PVA gels attracted particular attention in
the areas of drug delivery. The porous polymeric network of PVA cryogels, which
consists of crystalline regions (~3nm) and amorphous regions (~19 nm), regulates the
transport process of drugs throughout the matrix [158]. The research concluded that the
diffusion of solutes from hydrogels is related to the mesh size (i.e., the open space
between polymer chains), which is inversely correlated to crystallinity. Hydrogels with
higher crystallinity generally have smaller mesh sizes, which would impede the release of
entrapped macromolecular drugs [162]. Small drug molecules with a dimension smaller
than the mesh can move freely through the network, while the migration of larger
molecules such as proteins will be retarded [163,164]. As such, the mesh size can be an
effective tool for modulating drug loading and controlled release.
The biodegradation, in contrast to the stability, represents an event where the materials
degrade, the products become resorbed and disappear via metabolic routes [165].
Biodegradable/bioresorbable materials are particularly advantageous to be used for DEBs
as they allow multiple benefits such as reduced tissue inflammation, controlled drug
release, and repeatable interventions [166]. PVA-based commercial DEBs: DC Bead®
and DC Bead LUMI® are not degradable. Luckily, material compounding and blending
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provides two effective strategies to make PVA gels degradable. Bannerman et al.
introduced IONPs to the PVA hydrogels through in situ co-precipitation [140]. IONPs
were allowed to interact with PVA chains during the subsequent freezing-thawing cycles
and provide a certain degree of crosslinking to PVA. As a result, the gradual dissolution
of IONPs in an acidic environment would weaken the linkages and lead to the
dissolution/degradation of PVA. Another approach to construct degradable PVA
hydrogels is through blending. PVA has been blended with degradable hydrogels such as
chitosan [167], sodium alginate [168] and gelatin [150]. As intermolecular hydrogen
bonding is formed throughout the polymer blends, the degradation of the other polymers
can unfold the crystal chains and result in PVA dissolution [169,170].

2.7.2

Iron Oxide Nanoparticles

Nanotechnologies have emerged as a powerful tool in cancer therapy and the diagnosis of
diseases [171]. Among all the nanomaterials, iron oxide nanoparticles (IONPs) have
gained particular interests due to their excellent magnetic properties and biocompatibility.
IONPs have been extensively investigated for widespread biomedical applications, such
as magnetic drug targeting, magnetic resonance imaging (MRI), gene therapy and
hyperthermia/thermal ablation [172]. The most studied IONPs are magnetite (Fe3O4),
maghemite (𝛾-Fe2O3) and hematite (𝛼-Fe2O3) nanoparticles (NPs).
IONPs are commonly prepared by two chemical approaches: co-precipitation and thermal
decomposition. Co-precipitation involves the simultaneous precipitation of ferrous (Fe2+)
and ferric (Fe3+) ions in an alkaline environment. The mechanism of magnetite NPs
formation can be described by the following reactions [122]:
Fe3+ + 3OH − = Fe(OH)3

(1)

Fe(OH)3 = FeOOH + H2 O

(2)

Fe2+ + 2OH − = Fe(OH)2

(3)

2FeOOH + Fe(OH)2 = Fe3 O4 + 2H2 O

(4)
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The overall reaction can be represented by:
2Fe3+ + Fe2+ + 8OH − = 2Fe(OH)3 Fe(OH)2 → Fe3 O4 + 4H2 O

(5)

The size, shape and composition of the magnetite NPs can therefore be tuned by altering
the experimental parameters, including Fe2+/Fe3+ molar ratio [173], pH [122],
temperature [174], choices of iron precursors (e.g., chloride, sulfate or nitrate) and
alkaline agents (e.g., NaOH, NH4OH or isopropanolamine) [175–177]. While the coprecipitation process is the most simple and efficient approach to synthesize IONPs, the
products often develop a low degree of crystallinity and large size distribution [177].
In contrast to co-precipitation, thermal decomposition is performed in a non-aqueous
environment and can better control the size, shape, and polydispersity of IONPs [178]. In
a thermal decomposition reaction, organic complexes of iron (e.g., iron oleate, iron
oxyhydroxide or iron pentacarbonyl) decompose at elevated temperatures in the presence
of non-polar solvents and surfactant capping agents [179]. Surfactants are crucial in this
process because they modulate the nucleation and growth of the IONPs to ensure good
mono-dispersity [180]. The concerns with thermal decomposition are high temperatures
and toxic residuals of the organic chemicals employed [178]. In addition, the nonhydrolytic nature of the reaction renders IONPs with hydrophobic surfaces, which
imparts additional modification steps to make water-dispersible and stable IONPs that are
suitable for biomedical applications [181]. Of note, for both synthesis routes, with the
addition of oxidizing agents (e.g., HNO3), 𝛾-Fe2O3 or 𝛼-Fe2O3 can be synthesized [182].
Iron oxide nanoparticles must be endowed with the specific characteristics required for
targeted biomedical applications. The first and foremost properties are always
biocompatibility and toxicity [183]. IONPs are generally considered as safe,
biocompatible and non-toxic materials. The median lethal dose (LD50) of the bare IONPs
is 300-600 mg/kg body weight. Dextran coating could effectively improve the stability
and biocompatibility of IONPs and increase this number to 2,000-6,000 mg/kg [184].
Due to the broad safety margin of IONPs, a number of surface-coated IONPs have been
clinically approved as MRI contrast agents, such as ferumoxide, ferumoxtran and
ferumoxytol [185].
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The biodistribution of IONPs is dependent on the administration route and
physicochemical factors, such as size, porosity, charge and surface chemistry [186]. For
intravenously injected IONPs, they are removed from the circulation majorly by the
mononuclear phagocyte system. It has been reported that IONPs with a hydrodynamic
size (dH) > 100 nm quickly accumulate in the liver and spleen through macrophage
phagocytosis. In contrast, particles with d H <10-15 nm are most likely to be eliminated
through the kidney in a non-phagocytizing pathway [183]. The internalized IONPs are
metabolized in the lysosomes. The acidic pH environment and intracellular iron chelators
(e.g., phosphate, nucleotides and dicarboxylic acids) can solubilize IONPs into free irons
[187]. These irons would subsequently enter the intracellular iron pool and be utilized in
the production of hemoglobin and transferrin, thereby becoming part of the normal iron
pool [185]. The excess irons are stored in ferritin or exported by ferroportin, in order to
maintain the iron concentration within limits to avoid toxicity [188,189].
Another crucial property to support the biomedical applications is the magnetic
properties, particularly superparamagnetism, as it is highly relevant to MRI, hyperthermia
and magnetic drug targeting. In the presence of a magnetic field, the magnetic moments
of superparamagnetic materials could align with the direction of the field without any
remanence magnetization. Fe3O4 and 𝛾-Fe2O3 NPs are the two major superparamagnetic
iron oxide nanoparticles (SPIONs) employed in research and clinical studies. Their high
saturation magnetization values (Ms 70-100 emu/g) [190–192] allow generation of large
magnetic dipoles thereby local magnetic field gradient within the NPs, which will
strongly alter the spin-spin (i.e., transverse, T2) relaxation times of surrounding water
protons, resulting an enhanced imaging contrast [88]. Generally, SPIONs (~16-200 nm)
are used as negative contrast agents for T2-weighted MRI, while smaller (<15 nm) IONPs
are effective as T1 (i.e., positive) contrast agents [193]. In addition, the relatively high Ms
values of SPIONs would also allow precise spatial control over the particles in the blood
using an external magnetic field generated by a magnet or MRI coil. This activity has
been translated into magnetic drug targeting and MRN, as described in section 2.5.4. The
current challenges with MRN are in designing gradient coils to ensure stronger propelling
force [194].
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Moreover, SPIONs can respond to an alternating magnetic field and convert the magnetic
energy to heat within the particles. The heat generated can be used to elevate the
temperature of the surrounding tissue. The effectiveness of hyperthermia relies on the
fact that a temperature between 41-43 °C can cause tumor cell death, as they are less
tolerant to heat than normal cells [195,196]. In hyperthermia treatments, SPIONs can be
administered intravenously or intratumorally. Particle concentration should be large
enough to deliver a sufficient heating effect.
Despite the great potential of IONPs in diagnostic imaging and drug delivery, the
limitations with using such particles as an individual delivery system are also obvious:
poor colloidal stability, short blood circulation, burst release, limited drug loading
capacity, plasma protein adsorption, and unregulated biodistribution and
pharmacokinetics [183].
To address these limitations and further expand the applications of IONPs, a composite
platform named ferrogel (i.e., the combination of hydrogels with IONPs) was developed
[197]. Ferrogels can be prepared mainly via three routes: blending, in situ coprecipitation, and grafting-onto. They can be further classified into polymer-first (in situ
co-precipitation) and particle-first (blending and grafting-onto) approaches [198]. The
scheme for the three approaches is shown in Figure 2.3. Depending on the choice of
materials and the preparation methods, IONPs can form different interactions with the
hydrogel matrix. The blending method consists of a sequential preparation, where IONPs
are synthesized separately and added to a hydrogel precursor solution. The mixture is
then stabilized by the crosslinking of the hydrogel. While being facile, the blending
method fails to achieve a uniform nanoparticle distribution within the polymeric network.
Moreover, particles remain attached mainly through physical entanglement and hydrogen
bonding with the polymer chains [199]. Due to the limited particle-hydrogel interactions,
IONPs might diffuse out from the hydrogel upon swelling [200]. In the in situ coprecipitation process, the hydrogel matrix acts as the reactor. In detail, hydrogels are
firstly crosslinked through chemical or physical routes. The IONP precursors (Fe2+ and
Fe3+) are prepared in a stoichiometric ratio and mixed with the crosslinked hydrogel to
form a homogenous solution [122]. The gels are subsequently immersed into an alkali
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solution for the IONPs to precipitate. The mechanism with which IONPs are immobilized
in the gel was not fully elucidated. However, it is believed that the IONPs participate in
the polymeric network formation through hydrogen bonding with the hydrogel chains
[140,201,202]. In situ co-precipitation provides improved IONP dispersion in the
hydrogels. However, this method is limited to alkali-resistant polymers and should also
be avoided in hydrogel systems containing bioactive compounds, such as proteins and
cells, as the harsh environment may damage their bioactivity [203]. Compared to
blending and in situ precipitation methods, the grafting-onto approach provides particlehydrogel interactions through covalent bonds in addition to hydrogen bonds and van der
Waals forces [204]. In the grafting-onto method, IONPs serve as the crosslinkers to the
hydrogel monomers. In detail, IONPs are initially functionalized with reactive moieties
(e.g., -NH2 and -COOH). The nanoparticles are then added into a monomer solution to
form covalent bonds with the monomers when polymerized. As the IONPs are covalently
bonded to the network, the stability of ferrogel is guaranteed [125]. In the future, the
grafting-onto method would benefit from research efforts in simplifying the preparation
cycle and fabrication process [200].
A
Crosslinking

B
Alkali treatment

Magnetic hydrogel

C

Crosslinking

Magnetic hydrogel
Hydrogel monomer

IONP

Crosslinker

Fe3+

Fe2+

Functionalized IONP

Figure 2.3 Schematic of ferrogel preparation. (A) The blending method. (B) The in
situ precipitation method. (C) The grafting-onto method.
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Overall, IONPs have been helpful in the development of multimodal therapeutic
strategies, enabling a simultaneous exertion of therapeutic effect, hyperthermia and
diagnostic imaging. Further research could focus on the development of self-healing
materials and magnetically sensitive smart hydrogels [203]. Despite the wide range of
applications, the cytotoxicity and long-term fate of magnetic materials, including
individual particles and ferrogels, have yet to be fully revealed. As such, in vivo studies
using animal models should be continued to supplement in vitro findings.

2.7.3

Silica Particles

Considerable research efforts have been made in developing silicate materials for
biomedical applications. Silica (also known as silicon dioxide, SiO2) has been "generally
recognized as safe" by the FDA for more than five decades and is widely used in the food
industry as a color or formulation stabilizer [205,206]. Among all types of silica, SiNPs
plays a particularly critical role in fulfilling the rigorous clinical requirements for disease
diagnosis and controlled drug release. The presence of abundant surface silanols (Si-OH)
allows the conjugation of various organic functional groups, rendering SiNPs with a high
level of versatility for drug delivery applications [207].
SiNPs are predominantly synthesized via the sol-gel process. Both hydrolysis and
condensation can be acid- or base-catalyzed. Sol-gel process typically involves the
hydrolysis and condensation of alkoxide precursors [e.g., Si(OC2H5)4 or TEOS] in the
presence of alcohols (e.g., ethanol), water and catalysts (e.g., NaOH or HCl). The
simplified reactions that form SiNPs can be represented by [208]:
Hydrolysis: Si-(OR)4 + H2O ⇌ HO-Si-(OR)3 + ROH

(6)

Condensation: (OR)3-Si-OH + HO-Si-(OR)3 ⇌ (OR)3-Si-O-Si-(OR)3 + H2O

(7)

where R=alkyl group
The reaction forms a discrete, colloidal suspension (i.e., sol). The colloidal particles (1100 nm) within the sol then condense to form an interconnected, rigid network with pores
and polymeric chains (i.e., gel). The viscosity of the solution increases sharply at gelation
and can eventually form a solid object in the shape of the mold [209]. The final product
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of the sol-gel process is profoundly affected by the rate of hydrolysis and condensation
reaction [210]. In an acidic environment, hydrolysis is slow. The silica tends to form a
linear, weakly crosslinked network. Gelation proceeds by the formation of additional
branches and the entanglement of polymeric chains. As a result, acid-catalyzed sol-gel
generally leads to a gel structure [211]. In contrast, hydrolysis and condensation are fast
in the basic-catalyzed process [208]. This results in the rapid formation of highly
branched and non-interpenetrable clusters [209]. The clusters collide and lead to larger
aggregates through hydrogen bonding and van der Waals interactions. At a critical
concentration, the aggregates will precipitate in the form of discrete species as SiNPs
[210]. Various mechanical (e.g., centrifugation) and physical (e.g., oven drying and
alcohol dehydration) techniques can accelerate the water removal hence the formation of
SiNPs [211].
As the pH conditions lead to silica networks with distinct properties, it is not surprising to
see that each catalytic condition has its own characteristic applications. Acid-based solgel synthesis is predominately utilized in the development of nanocomposite hydrogels.
Namely, the reaction occurs in the presence of hydrogels to form SiNPs-embedded
hydrogels. The relatively slow hydrolysis step would result in molecular chains contain
sufficient silanol groups to participate in hydrogen bonding with the hydrogel polymers
[209]. The formation of SiNPs-hydrogel interaction affects the intramolecular bonding of
the polymeric chains; therefore could help modify the mechanical properties and
permeability of the gels [212–214]. For example, a silica/PVA composite hydrogel was
prepared by in situ sol-gel synthesis [213]. SiNPs possessed good dispersion in the
hydrogel matrix and developed strong interaction with PVA through Si-O-C bonds.
Results showed that SiNPs served as a stiffness enhancer to PVA. A greater mass
percentage of SiNPs in the PVA increased Young's modulus by up to ~14 folds.
Similarly, silica/PVA nanocomposite hydrogel was prepared and electrospun into
nanofibers [215]. The author found that the in situ formation of SiNPs contributed to the
crosslinking of PVA, which reduced the -OH available for hydrogen bonding with water.
As a result, the PVA exhibited improved aqueous stability.
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Base-catalyzed mechanism is widely employed in the preparation of discrete SiNPs. Such
a process is considered simple, fast and allows precise size and morphology control
[216]. Stö ber and Fink pioneered this approach in synthesizing non-porous silica spheres
in the range of 50-2000 nm [217]. The authors found that particle size was dependent on
the type of alcoholic solvents, silica precursors, and the concentration of water and
ammonium hydroxide. The resulting non-porous silica particles are extensively used as
hydrogel nanofillers [218], stabilizing agents [205,206] and matrix for protein adsorption
study [219]. The applications of non-porous silica particles have been extended into drug
carriers after surface modification with appropriate functional groups [220].
Base-catalyzed sol-gel process has also been adopted to prepare mesoporous SiNPs (i.e.,
SiNPs with pores sizes in the range of 2-50 nm) [221,222]. Amphiphilic copolymers or
cationic surfactants are essential in the synthesis of porous SiNPs, as they serve as pore
template and determine pore size. Templates with longer chain lengths typically result in
larger pores [223]. As the drug transportation within non-functionalized porous SiNPs is
through diffusion, the pore size and volume must be carefully designed to modulate the
payload loading and release. Greater pore size and volume generally result in larger
loading and faster release than particles with smaller pores [224]. This could be explained
by the steric hindrance effects inside the mesopores [225]. Mesoporous SiNPs with extralarge pores (~25 nm) are extremely helpful in the loading and release of proteins,
enzymes and DNA vaccines [223,226,227].
Sol-gel SiNPs, either in porous or non-porous form, are semicrystalline material and
susceptible to hydrolytic attack, which encourages the degradation and clearance of
SiNPs in vivo. The degradation process contains multiple stages: hydration, hydrolysis
and ion exchange. The silica framework will eventually be converted to silicic acid
(Si(OH)4, pKa 9.6), a water-soluble compound [228]. The rate of dissolution is largely
dependent on the physicochemical properties of the particles [229], pH [230] and
composition of the dissolution media [231]. Silicic acid is non-toxic and has a natural
promoting effect on bone mineral density [232]. The degradation product can diffuse
through the bloodstream or the lymphatic system. The ultimate excretion is through urine
by the kidney [233].
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In conclusion, SiNPs have gained growing interests as an advanced platform for
biomedical applications. For future directions, more studies are expected in the
evaluation of the toxicity, biological stability, and efficacy of SiNP-based delivery
systems. Innovations could be made in designing targeted, stimuli-responsive platforms
for gene and vaccine delivery [234].

2.7.4

Proposed Systems

This thesis covers three multifunctional delivery systems. The research work of Chapter 3
and Chapter 5 is based on composite hydrogel microparticles, while Chapter 4 contains
work on the silica nanoparticles.
Chapter 3 PVA-IONP microparticles
Chapter 3 describes a multifunctional ‘nano-on-micro’ drug delivery system. Figure 2.4
shows the composition of the system. In detail, magnetite (Fe3O4) nanoparticles were
immobilized in the PVA matrix via in situ co-precipitation followed by freezing-thawing
process. The targeted particle size is 100-300 𝜇m, as the beads in this size range are
preferred in clinics due to the effective local necrosis and less systemic complications
compared to larger ones [62–64].

Figure 2.4 Schematic drawing of a multifunctional PVA-IONP microparticle.
The PVA-IONP microbeads are promising candidates for embolic DEBs in TACE
therapy due to the following reasons: the avoidance of toxic chemical crosslinkers; the
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ability to embolized tumor-supplying vessels; drug loading and controlled release
capacities; the co-localization of drug with contrast agent; the potential for targeted drug
delivery through image-guided magnetic resonance navigation (MRN) of the
superparamagnetic microparticles; the possibility for repeatable TACE treatments, as the
degradation of microbeads can occur with the dissolution of IONPs and the disintegration
of PVA matrix.
Chapter 4 SiO2 nanoparticles
The protein delivery system is based on non-porous SiNPs, as shown in Figure 2.5.
SiNPs were synthesized by Stöber process and loaded with bioactive proteins via
adsorption. SiNPs interact with proteins through hydrogen bonding and electrostatic
interactions. The targeted size of the protein carrier is 100-400 nm, as it can provide a
reasonable residence time on the ocular surface [235–237]. Such delivery system can
potentially fulfill several roles: protection from protein decomposition, sustained release
and tunable release profile. The system is hypothesized to be helpful in topical delivery
of protein therapeutics to treat dry eye disease by reducing the dosing frequency and
allowing personalized drug dosage.

Figure 2.5 Schematic drawing of the bioactive protein delivery system.
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Chapter 5 PVA-SiO2-IONP microparticles
The formulation described in this chapter is a continuation and optimization of the PVAIONP system. The multifunctional drug carrier in Chapter 5 is comprised of a PVA
matrix, loaded with IONPs and SiO2 microparticles (Figure 2.6). Similar to the PVAIONP system, PVA-SiO2-IONP microparticles are anticipated to be beneficial for
application as DEBs for TACE treatment.

Figure 2.6 Schematic drawing of a multifunctional PVA-SiO2-IONP microparticle.

2.8

System Assembly using Microfluidics

Microfluidics will be used to produce our microparticulate multifunctional drug carriers.
The materials and fabrication techniques for microfluidic chips, droplet generation
mechanisms, and channel configurations will be reviewed in this section. The advantages
of using microfluidics in fabricating drug delivery systems will also be discussed. The
detailed fabrication approach will be described in Chapter 3 and Chapter 5.

2.8.1

Materials and Fabrication Techniques for Microfluidic Chips

Poly(dimethylsiloxane) (PDMS) is the most common microfluidic material employed in
research laboratories due to its convenient fabrication by soft lithography and reasonable
cost [238]. Devices with 3D structures or multilayers can be prepared via curing
individual pieces at mild temperatures (40-70 °C) and stacking [239]. The ability to
exchange oxygen and carbon dioxide expands its application into cell-related research
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(e.g., biological interactions, cell sorting, bioanalysis and diagnostics) [240–242].
However, the alkyl groups attached to PDMS’s Si-O backbone lead to nonspecific
adsorption and swelling. More specifically, hydrophobic molecules and biomolecules
could adhere to channel walls and lead to channel clogging and inaccuracy in the
measurements [243,244]. Another drawback is the incompatibility with organic solvents
[245]. Upon exposure to organic solvents such as acetone, swelling of the channel would
affect droplet generation and device deformation [246]. Surface modifications of the
PDMS with hydrophilic moieties can address these issues, but the challenges arose in
maintaining the long-term stability and hydrophilicity of the modified surface [247,248].
PMMA has gained interests as an alternative to PDMS. PMMA is particularly useful for
disposable chips because of its fairly good rigidity, chemical resistance, transparency and
biocompatibility [249]. In general, PMMA microfluidic microdevices consist of channel
plates and cover plates that need to be sealed together. The channel plate can be created
using a wide range of techniques [250], including hot embossing, laser ablation,
imprinting, molding and solvent etching, making them desirable for mass manufacturing.
However, creating uniform surface bonding of the two plates without deforming the
channel structure represents a significant barrier for industrial fabrication. A number of
approaches have been explored: thermal, solvent, adhesive, or polymerization bonding
have demonstrated robust bonding [250]. Similar to PDMS, biocompatible PMMA
microdevices with predefined geometry are extremely useful in bio-related fields.
However, the hydrophobic nature of PMMA resulted in nonspecific adsorption and poor
wetting properties at the channel wall. To overcome these challenges, various surface
modification [251] and bulk modification [252] methods been developed.
Hydrogel is another class of material that can be used to make microfluidics. Chips made
from hydrogels have particular interests in biological applications and biomimicking due
to their similarity with extracellular matrix (ECM). The porous, 3D and water-rich
polymeric environment allows the diffusion of cell nutrients and growth factors, making
it a promising substrate for cell culture and encapsulation [253]. Gel-based microfluidic
devices can be fabricated by soft lithography, flow solidification and gel
photopolymerization [254]. The limitations with gel-based microchips are: (1) low spatial
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resolution in microfabrication (micrometer scale) compared with other polymers
(nanometer scale), (2) limited capacity supporting thick layer cell culture, (3) channel
sealing (surface bonding) is difficult [254–256]. Efforts in exploring alternative
micropatterning and integrative methods as well as materials could possibly address these
challenges in the future.
Inorganic materials, including silicon and glass have been used for microchips even
before the concept of 'microfluidics' has emerged. Silicon and glass microfluidic channels
are typically made by photolithography and chemical etching [257]. Due to their good
thermostability and solvent resistance, silicon/glass microdevices become a key platform
for lab-on-chip design, droplet generation and bio-separation [258]. The drawbacks with
such devices are associated with the sealing of the two plates and the relatively expensive
and time-consuming fabrication process [257,259]. A picosecond pulsed laser system has
been adopted and demonstrated feasibility in addressing the issues mentioned above
[259].

2.8.2

Droplets Generation Mechanisms

Droplet microfluidics (or droplet-based microfluidics) is a subdivision of microfluidics
that aims at producing and manipulating individual droplets. The generation of slugs or
discrete volumes in microchannels replies upon immiscible multiphases [260]. A
continuous phase is referred to the liquid in which droplets flow, while a dispersed phase
is the droplet phase.
The mechanisms of droplet formation have been studied in depth. Reynolds number (R e)
is the dimensionless parameter in fluid mechanics used to predict flow patterns [261]. It
correlates the relative effect of inertia forces to viscous forces [262]. R e is defined as:
Re =

ρDν
μ

(8)

where 𝜌 is the density of the fluid, D is the diameter of the passageway, 𝜈 is the velocity
of the liquid, and 𝜇 is the viscosity of the liquid. Laminar flow represents a flow with
parallel streamlines without disruption. Turbulent flow characterizes non-linear, irregular
fluctuations for mixing in the liquid. The limit of laminar flow between laminar and
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turbulent flows is marked by R e of ~1,800-2,000 [263]. As the diameter D and velocity 𝜈
are relatively small for the fluids in the microchannels, droplet microfluidics typically
falls in a low Reynolds number (usually much less than 100, often less than 1.0) laminar
regime [264,265]. As such, inertial effects in the flow are negligible-the flow is
dominated by viscous stresses [265].
In a microfluidic device, the confinement of the channels enhances the surface-to-volume
ratio of the fluids, which consequently leads to the enhancement of surface tension and
fluid viscous force [264]. The negligible inertial effects leave interfacial tension and
viscosity in competition with each other [266]. When the two immiscible phases were
introduced together, the continuous phase disrupts the dispersed phase due to the viscous
forces. The mixing would introduce nonlinearity and instability at the junction of two
microchannels where the dispersed phase would break into droplets or plugs due the
tendency of surface tension to minimize the interfacial area [267,268].
The relative effect of viscous force and surface tension can be measured by the capillary
number Ca :
Ca =

μν
γ

(9)

where 𝜇 is the viscosity of the continuous phase, 𝜐 is the superficial velocity of the
continuous phase, and 𝛾 is the interfacial tension or surface tension between the two
fluidic phases. At low capillary numbers, surface tension dominates, and the droplets
remain spherical (dripping model). As the Ca increases, viscous forces increase. The
shear stress applied to the droplet is large enough to overcome the surface tension. The
initially spherical droplet becomes ellipsoidal plugs and eventually breaks into smaller
droplets further downstream (jetting model) [269–271]. The balance of the two forces
determines the flow pattern whether droplets (dripping) or plugs (jetting) form under a
given condition. In general, droplets generated in dripping regimes are smaller in
diameter with narrower size distribution [271,272]. As such, the dripping mode is
preferred in droplet microfluidics.
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2.8.3

Geometrical Design of Microchannels

The droplet generation mechanisms are adapted to guide the microparticles fabrication.
Both passive and active techniques can be used to produce uniform and evenly
distributed droplet volumes ranging from femtoliters to nanoliters. In active droplet
production, microchannels in predesigned configurations are required to enhance the
viscous shear force to secure the continuous formation of droplets.
Three primary microfluidic channel geometries are used: co-flow, T-junction and flowfocusing (Figure 2.7). In a co-flow geometry, also called coaxial flow, a cylindrical glass
capillary is coaxially inserted into square glass tubes. The dispersed phase flows in the
capillary in parallel to the continuous phase placed in a larger-diameter glass tube. The
continuous phase surrounds the dispersed phase, and the droplets are generated mainly by
the instability of the dispersed phase due to surface tension (Rayleigh-Plateau instability)
[268]. The size of droplets can be tuned by the fluid properties and flow rates [271]. The
cylindrical geometry of the center capillary limits the geometry of co-flow devices to a
3D architecture. In contrast, the T-junction and flow-focusing are applicable in planar
geometries but possess more complicated droplet breakup mechanisms [266]. T-junction
design is a subdivision of cross-flow designs, where the dispersed phase is sheared at an
angle θ (0° < θ < 180°). In the T-junction category, the dispersed and continuous phase
flow in orthogonal channels meet at a cross-junction. The viscosity of two fluids,
interfacial tension and channel geometries can affect the droplet formation [273]. The
flow-focusing design is similar to co-flow. The continuous streams flow on both sides of
the dispersed phase to a focus unit, where the three streams are forced through in a
condensed passageway. The extended pressure and shear stress generated by the
continuous phase breaks the dispersed phase inside or downstream of the orifice [274].
The droplet size can be controlled by the viscosity of the two phases, flow rates and inlet
pressure [275]. In general, passive technique allows the coefficient of variation (CV),
defined as the standard deviation in size divided by the mean droplet diameter, to remain
less than 3% [276].
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(A) Co-flow

(B) T-junction

(C) Flow-focusing

Figure 2.7 Schematic illustration of different channel geometries of a microfluidic
device. (A) Co-flow; (B) T-junction; and (C) flow-focusing. Solid arrows indicate the
flow direction.
Active methods implement external forces to exert local actuation to break up the fluid
stream physically. The co-flow, T-junction and flow-focusing channel geometries still
apply, and additional pneumatic, acoustic forces and magnetic forces are introduced to
produce droplets on demand [277]. Active mixing purposely creates chaotic motion in the
device, which promotes mass transfer. This expands the application of microfluidics into
bioreactors for cells or bacteria since it accommodates fast and adequate oxygen and
nutrients transfer [278].

2.8.4

Droplet Microfluidics in Drug Delivery

Droplet-based microfluidics enables precise and reproducible production of micro- or
nanocarriers as drug delivery systems. This technique renders several advantages over
conventional bulk production, including tailored particle size and encapsulation of
various types of drugs.
Tailor microparticle size to tumor arterial anatomy
DEB size is one of the key parameters that would affect the procedure outcome. Animal
studies have suggested that smaller size DEBs (70-150 𝜇m) had deeper tissue penetration
and greater drug coverage (i.e. amount of tissue exposed to drug) than the beads in the
standard size range (100-300 𝜇m) [279]. Eddy and Casarett claimed that tumor vessels
maintained a capillary-like structure. Capillaries are typically less than 12 𝜇m in
diameter, and some vessels that could progressively dilated and reached diameters ~200
𝜇m based on their studies on the hamster [280]. It has been advised that the human
tumor blood vessels were much larger in diameter than what would be predicted based on
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animal models [281]. Moreover, the diameter of tumor is also histology- and locationdependent [18]. These variants in tumor vasculature suggest that providing DEBs in
several size ranges is necessary.
Microfluidic fabrication allows reproducible fabrication of particles of size over a broad
size range (10-1000 𝜇m). Particles of different sizes can be simply prepared by tuning the
flow rates or properties of the dispersed phase or continuous phase [282,283]. The
particles are highly uniform in size with CV < 3% [276]. Microparticles in defined
geometry could be advantageous in DEB application, as they can provide predictable
drug eluting profile and embolization outcome.
Encapsulation of various types of drugs
In microfluidics, drug molecules could be encapsulated into the carriers through single
emulsions, multiple emulsions or hierarchical porous particles. For single emulsion
templated particles, drugs can be suspended in a dispersed phase and encapsulated into
the particles through forming oil (O)-in water (W) or W/O emulsions [284,285]. For
double emulsion systems, W/O/W configuration is typically used. Drugs are encapsulated
in the internal water phase of the double emulsion and can improve the stability and
solubility of the drugs [286,287]. In addition to encapsulation, porous nanoparticles-inmicrocarriers provide another approach for high drug loading via physical adsorption at
pore surfaces [288,289].
Microfluidics techniques expand the material selection and ease the loading of drugs with
various properties. In conventional preparation of delivery systems, hydrophilic drugs are
generally loaded into hydrogel particles [106], while lipophilic drugs are mostly limited
to liposomes and solid lipid nanoparticles [290]. With the aid of microfluidic techniques,
both hydrophilic and lipophilic payloads can be encapsulated into the delivery vehicles
[144]. Multiple drugs loading can be realized by microfluidic fabrication of
microparticles with multiple compartments for separate encapsulation of drugs. For
example, core-shell particles were prepared via double emulsion templates, hydrophilic
therapeutics DOX was loaded into gelatin methacryloyl (GelMA) cores, while
hydrophobic actives camptothecine (CPT) was loaded into the PLGA shells [291].
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Similarly, Winkler et al. prepared Janus particles for simultaneous delivery of a
hydrophilic-hydrophobic drug pair. Acetaminophen (APAP, hydrophilic) was entrapped
in inner water droplets within an oil phase containing naproxen (NPX, hydrophobic), the
W/O emulsion was then stabilized in another aqueous solution to form a W/O/W
emulsion [292]. He et al. fabricated dual-/triple-compartmental microparticles using a
novel W/W template [293]. Each compartment is a W/W droplet consist of calcium
alginate (Ca-Alg) as the shell material and sodium carboxymethylcellulose (CMC) as the
inner fluids. The compartments were aligned by needles and then fixed via Ca2+
crosslinking in the outer layer of Ca-Alg. The dual compartments in the resultant capsules
were used separately to load two distinct model drugs.

2.9
Clinical Applications and Future Translational
Opportunities
Multifunctional microparticles offered several improvements to the current DEBs (Table
2.6). Namely, the prepared system could be delivered through a catheter or even MRN.
The co-localization of contrast agent and drug allows a more precise tracking of the drug
distribution relative to the tumor site through MR imaging. This would provide useful
information for intra- and post-procedural evaluation of the TACE procedure. Moreover,
the delivery system can potentially render a controlled drug release to maintain an
effective local drug dosage. The IONPs and silica particles participate in the crosslinking
of PVA and render additional functionality through the particle-PVA interactions. More
specifically, the composite hydrogel would disintegrate as the IONPs and (or) silica
dissolve, which would allow the elimination from the embolization site with due course
of time, which would allow repeatable TACE treatments. Besides, one or more drugs can
be possibly loaded. In addition to treating the intermediate HCC, multifunctional
microparticles can be applied in managing colorectal liver metastases [294].
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Table 2.6 Comparison of current DEBs with multifunctional microparticles.

New polymeric platforms must be developed to allow the integration of multiple
desirable functions described in section 2.5. The development of novel material strategies
will also expand the drugs amendable to hydrogel-based systems. A combinational
treatment regimen might be possible with a wide range of functional particles and
bioactive molecules becoming compatible with the DEBs. Several microparticulate
platforms have demonstrated the viability for combined regimens, including
hyperthermia-TACE [295] and stem cell therapy-chemotherapy [296]. These may
improve the clinical outcome of the treatments.
Multifunctional nanoparticles provide protection and sustained availability to therapeutics
compared to free dosage forms. Improvements could be made through surface
functionalization and introducing porous structure [211]. Nanocarriers can be used alone
or incorporated into existing platforms, such as hydrogels or contact lenses to construct
drug-eluting medical devices. Future studies on the safety and effectiveness must be
warranted to validate their potential benefits.

2.10
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Chapter 3

3

Development of Multifunctional PVA-IONP
Microparticles for TACE1
3.1

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third
most common cause of cancer-related death [1]. Potentially curative treatments, including
liver transplantation, surgical resection, or radiofrequency ablation, are reserved for
patients with early-stage HCC. However, 50% of patients with HCC are diagnosed at
intermediate or advanced stages due to the poor prognosis, precluding curative-intent
options [2].
Transarterial chemoembolization (TACE) plays a vital role in the clinical management of
HCC. According to the most frequently used BCLC algorithm for HCC, TACE is
recognized as first-line therapy for patients with multinodular HCC and preserved liver
function (BCLC stage B) [3,4]. Besides, TACE is commonly recommended as the
bridging therapy to downstage patients waiting for liver transplantation [5]. The role of
TACE in HCC management continues to evolve, as TACE was evidenced to be an
effective option in managing recurrent HCC after curative treatments [6,7].
TACE combines transarterial embolization (TAE) with the infusion of
chemotherapeutics. It can be performed through conventional TACE (cTACE) and drugeluting beads TACE (DEB-TACE). cTACE involves the catheter-guided delivery of
antineoplastic drugs using Lipiodol-based emulsion, followed by administration of
embolic agents to achieve a synergistic effect of drug cytotoxicity and ischemia [8]. For
DEB-TACE, embolic particles are loaded with anti-tumor drugs before their transarterial
administration. As such, a simultaneous exertion of both therapeutic and embolic effects
can be possible. Although clear evidence of the superiority of DEB-TACE over cTACE

1

A version of this chapter will be submitted to Polymers under the title: Development of multifunctional
poly(vinyl alcohol) hydrogel microparticles for transarterial chemoembolization therapy. Xinyi Li will be
the first author.
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is yet to be found, the former technique offers a favorable pharmacokinetic profile with
an improved loading capacity and release profile, along with a more standardized and
repeatable hospital protocol [9–12].
The most commonly used commercial DEBs are DC BeadTM (Biocompatibles, United
Kingdom) and HepaSphereTM (BioSphere Medical, France), Embozene TandemTM
(Varian Medical Systems, United States) and LifePearl® (Terumo International Systems,
Belgium). These products are non-degradable, making repeat treatment impossible. Also,
imaging contrast agents have to be administered separately, leaving the location of the
beads and therefore the anti-tumor drugs rather imprecise.
Over the past decade, there has been a growing interest in designing magnetic and
degradable DEBs. Magnetic characteristic allows post-operational evaluation of particle
biodistribution and tumour response. Superparamagetism would be preferred as it permits
magnetic resonance imaging (MRI)-guided TACE. Degradable DEBs could address the
concerns of non-target embolization, ischemia-induced angiogenesis, and allow
repeatable treatments [13,14]. In addition, the integration of multiple functions, including
embolization, imageability, controlled release and degradation, would ideally permit a
safer, more effective and repeatable TACE treatment.

Physically crosslinked PVA hydrogel prepared using the low temperature thermal cycling
(LTTC) process has many desirable properties for DEB-TACE therapy [15]. However,
PVA hydrogel is known to be biostable and nondegradable. Our prior work demonstrated
that it is possible to design a ‘degradable’ PVA hydrogel with incorporated iron oxide
nanoparticles (IONPs) using the LTTC process. In this composite system, IONPs
contribute to the crosslinking of the PVA-IONP hydrogel. Since IONPs can degrade and
become soluble under physiological conditions and the slightly acidic tumor
environment, the composite hydrogel would ‘degrade’ via removal of the crosslinks and
redissolution [16]. The anti-cancer drug, doxorubicin (DOX), can be loaded into this
hydrogel system for locoregional delivery.
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In this work, we first fabricated iron-containing PVA hydrogels in the form of
microbeads using the microfluidic technique. Superparamagnetic iron oxide nanoparticles
were formed and anchored into the microbeads through in situ co-precipitation and LTTC
process. The morphological and structural characteristics of the resulting PVA-IONP
microparticles were examined by electron microscopy. The magnetic properties, MRI
contrast effect, and degradation were evaluated. Finally, DOX loading and in vitro
release were studied in simulated healthy tissue and tumorous conditions. PVA-IONP
microparticles obtained can successfully integrate multiple functions into a single system,
therefore it could be promising to be used as DEBs for TACE.

3.2
3.2.1

Materials and Methods
Materials

Poly(vinyl alcohol) (MW 146,000-186,000, 99+% hydrolyzed), iron (III) chloride
(FeCl3), iron (II) chloride tetrahydrate (FeCl2∙4H2O) and phosphate-buffered saline were
purchased from Sigma-Aldrich, sodium hydroxide (NaOH) pellets and Dulbecco’s
modified Eagle’s medium (DMEM) were obtained from ThermoFisher Scientific.
Hydrochloric acid (36.5%-38%) was acquired from Caledon. Span80 was obtained from
Fluka. Doxorubicin hydrochloride was purchased from Cayman Chemicals. Phosphate
buffer solution (pH 5.5) was prepared by a procedure reported elsewhere [17]. The rest of
the chemicals were all in ACS reagent grade and purchased from Sigma-Aldrich.

3.2.2

Assembly of the Microfluidic Device

A planar microchannel was milled out of a poly(methyl methacrylate) (PMMA) slab (50
x 25 x 12 mm) with a flow-focusing configuration. The continuous phase flow channel
dimensions were about 500 m in width, while the measured channel dimensions for the
dispersed phase were about 200 m. A second PMMA slab (50 x 25 x 12 mm) was
sealed onto the slab containing channels by screws. Liquids were supplied to the
microfluidic channel separately using two syringe pumps (NE-1000, New Era Pump
Systems Inc.). A 0.038” outer diameter tubing (Intramedic polyethylene tubing, BD) was
connected to the outlet hole to guide the droplets.
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3.2.3

Preparation of Dispersed Phase

Dispersed phase containing IONP precursors were prepared as described elsewhere [16].
Briefly, a 5.88 wt.% PVA stock solution was prepared by dissolving PVA powder in a
reactor at 90°C for 3 hours. Iron chloride solution was prepared by dissolving 6.20 g
FeCl3 and 3.80 g FeCl2•4H2O in 20 mL distilled water. The iron solution and PVA
solution were then mixed proportionally to make a final mixture containing 5 wt.% PVA,
1 wt.% FeCl3 and 0.6 wt.% FeCl2•4H2O. The resultant mixture was filtered through a
5μm filter (Acrodisc® syringe filter, Pall Laboratory) and used as the dispersed phase.

3.2.4

Microfluidic Fabrication of Microparticles

Undecane containing 1 wt.% Span80 was used as the continuous phase. The flow rate of
the continuous phase was set at 20 mL/h, while the dispersed phase flow rate was kept at
1 mL/h. The continuous phase was flushed through the microfluidic device for at least 30
seconds to convert the microchannel wall to completely hydrophobic. Droplets were
collected after a steady state was reached (~5min). A high-speed camera (Redlake
MotionScope M with a frame rate up to 1000 frames/sec) was used to image the beads
formation process.
The microdroplets generated were subsequently guided to a container containing 0.5
mol/L sodium hydroxide (NaOH) solution, whereby IONPs formed and the droplets
solidified. The resulting microbeads were further collected and washed with 50v/v%
ethanol in water several times and subject to six freeze-thaw cycles (FTCs) (from 20°C to
-20°C then to 20°C at 0.1°C/min, held for one hour at the temperature limits). After that,
the microbeads were stored in phosphate-buffered saline (PBS) at room temperature until
future use.

3.2.5

Microscopy Observation

Morphological observation and size analysis were first acquired from an optical
microscope (Olympus BX60) equipped with an OMRX A35100U camera. Samples were
prepared by dropping microbeads suspension on the microscope glass slides. The area of
the beads was measured manually using Image J software for over 100 samples (see
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Appendix A for an image used in this measurement) and then converted into an
equivalent spherical diameter using the following equation:
d = 2√A/π

(1)

where d is the equivalent spherical diameter and A is the measured sectional area of the
microbead.
Surface morphology was examined with a scanning electron microscope (SEM, LEO
(Zeiss) 1540XB FIB/SEM). Microbeads were dehydrated through to 100% ethanol by
incrementally increasing ethanol concentration. Critical point drying (Samdri PVT-3B)
was performed on the microbeads loaded onto a p-type silicon wafer with 0-10 Ohm-cm
resistivity and orientation of 100 (University Wafers). Before imaging, samples were
sputtered with a 5 nm osmium coating (Plasma Coater, Filgen). EDX was also performed
on these samples for elemental analysis.
Transmission electron microscopy (TEM, PhillipsCM10) was performed to reveal the
beads' microstructure and acquire the size and shape of internal IONPs. TEM samples
were prepared by dropping the microbead suspension onto the Formvar carbon-coated
400 mesh copper grids (Electron Microscopy Sciences) and dried in air.

3.2.6

Magnetic Properties

The PVA-IONP microbeads (75.24 mg/mL) were suspended were placed in a
microcentrifuge tube (ThermoFisher Scientific) filled with 1 mL PBS solution. A
permanent magnet was then introduced close to the tube for a selected time interval. The
movement of microbeads towards the magnet and their settling upon magnet removal was
recorded using a camera.
The hysteresis loop of dried microparticles was tested using a vibrating sample
magnetometer (VSM, LakeShore 7407, Lake-ShoreCryotronics Inc.) at 298 K.
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3.2.7

MR Contrast Effect

For the MR images, PVA-IONP microbeads were placed in 1.5mL centrifuge tubes at
varying masses. Neat 5wt% PVA hydrogel was homogenized and used as the control. All
tubes were filled with agar phantom material described elsewhere [18] and then placed in
a large plastic container also containing agar phantom material.
MRI contrast enhancement was examined using a clinical 3T MRI scanner (Siemens
Healthcare, Erlangen, Germany). Scans were performed at 350 ms repetition, 3.5-15 ms
echo-time, 3mm (axial) and 4mm (coronal) section thickness, 4.8 mm (axial) and 3.6 mm
(coronal) intersection spacing, 88x192 matrix size and 65x141mm field of view to
acquire T2-weighted images.

3.2.8

In vitro Degradation Measurements

Degradation of the PVA-IONP microbeads was studied by placing 1.5mL hydrated beads
(76 mg/mL) into a dialysis kit (2mL Mini Dialysis Kit, 1kDa, GE Healthcare) and
performing dialysis against 3 mL DMEM (pH=7.4, used as received; pH=5.5, adjusting
pH using HCl) at 37 C. At predetermined time points, the solution outside the dialysis
kit was collected, and the amount of released iron content was analyzed using atomic
absorption spectroscopy (AAS, Varian Spectra AA-55) at the wavelength of 248.3 nm.
Once the degradation medium was removed, the dialysis kit was placed in an equal
volume of fresh release medium. Each experiment was carried out in triplicate. To
determine the percentile of released iron, the total iron content of microbeads was
extracted by dissolving the microbeads using diluted HCl. The solubilized iron content
was subsequently quantified using AAS.

3.2.9

Loading and in vitro Release of DOX

Loading of DOX was achieved by soaking PVA-IONP hydrated microbeads (0.25 mL)
into a doxorubicin solution (equivalent DOX concentration 0.25 mg/mL, 1mL) at room
temperature overnight. The resulted products were collected by a permanent magnet and
washed several times with PBS to removed non-specifically absorbed drugs.
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The amount of doxorubicin in the supernatant was quantified using a UV
spectrophotometer (Cary 60 UV-Vis, Agilent Technologies Inc.) at 485 nm. The loading
capacity of doxorubicin was determined by Equation 2:
mg
Doxorubicin loading( ) = (W0 − Wt )/V b
mL

(2)

Loading efficiency was determined by Equation 3 as follows:
Loading efficiency (%) =

(𝑊0 −𝑊𝑡)
𝑊0

× 100%

(3)

where W0 is the initial weight of DOX in solution, Wt is the weight of DOX in the
supernatant, and Vb is the volume of hydrated PVA-IONP beads.
To study the in vitro release of DOX, drug-loaded microbeads were resuspended into 15
mL release buffer (PBS, pH=7.4 and phosphate buffer, pH 5.5) and then placed in a
shaking water bath (New Brunswick Scientific, USA) maintained at 37 C with gentle
shaking (rpm=110). At predetermined release intervals, a supernatant of 1 mL was
withdrawn from each sample and analyzed as described before. Subsequently, 1 mL of
fresh release media was added to the microbeads to keep the total volume constant.
The cumulative DOX release was calculated by Equation 4:
Cumulative DOX release (%) =

Mt
× 100%
M∞

(4)

where Mt is the amount of DOX released at time t, M∞ is the amount of DOX loaded on
the microbeads.

3.2.10

Statistical Analysis

For DOX loading study, a sample size of six was used. For DOX release and microbeads
degradation study, a sample size of three was used at each experimental condition.
Statistical analysis was performed using Microsoft Excel and OriginLab 2019b
(OriginLab Corporation, MA). Results are reported as the mean ± standard deviation.
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3.3
3.3.1

Results
Droplets Generation and Size Analysis

The dispersed phase was broken into droplets at the narrow orifice by continuous phase
(Figure 3.1). The droplets solidified in the NaOH solution and retained a teardrop shape.
All the microbeads exhibited brownish-yellow color (Figure 3.2 A). The microbeads
followed a relatively narrow size distribution with an equivalent spherical diameter of 95
± 22 μm (Figure 3.2 B).

Figure 3.1 Fabrication of PVA-IONP microbeads using a flow-focusing microfluidic
channel. The red arrow indicates flow of the dispersed phase, the blue arrow
indicates flow of the continuous phase, and the black arrow indicates the generated
microbeads. Droplets were successfully fabricated using a flow-focusing
microfluidic device.
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Figure 3.2 (A) Optical microcopy image of fabricated PVA-IONP microbeads and
(B) histogram of microbead equivalent spherical diameter fit to a Gaussian
distribution. Microbeads were in a teardrop shape with a relatively narrow size
distribution.

3.3.2

Morphological, Elemental and Structural Features of
Microparticles

The morphology of the beads was examined using SEM and results are shown in Figure
3.3 A-C. EDX analysis of the microbeads confirmed the presence of iron inside of the
beads (Figure 3.3 D-E).
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Figure 3.3 (A)-(C) SEM images of PVA-IONP microbeads. (A) displays a whole
bead, (B) and (C) show surface morphology. (D) Whole microbead with a square
specifying the location of EDX sampling. (E) EDX spectrum indicating the presence
of iron in the PVA-IONP microbeads.
Inspection of beads by TEM revealed the presence of iron in the form of IONPs with a
uniform spherical shape (Figure 3.4 A) with minimum aggregation. The size distribution
histogram showed a narrow size distribution of IONPs with a mean diameter of 11 nm
(Figure 3.4 B). IONPs were distributed at the interface of polymer-rich and polymer-poor
regions.
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Figure 3.4 (A) TEM micrograph of PVA-IONP microbeads. The black arrow
indicates an individual iron oxide nanoparticle, the red arrow indicates a polymerrich region, and the blue arrow indicates a polymer-poor region. (B) Histogram of
diameter of dispersed IONPs fit to a Gaussian distribution. IONPs were in spherical
shape with minimum aggregation. IONPs were observed to distribute at the
interface of polymer-rich and polymer-poor regions.

3.3.3

Magnetic Properties

The magnetic properties of microbeads were first examined visually in stagnant PBS.
Upon introducing the magnet, the beads moved towards it. Once the magnet was
removed, all beads slowly settled down due to gravity (Figure 3.5 A).
The magnetization study of PVA-IONP microbeads was performed at 25 C. The
symmetrical sigmoidal shape of the magnetization curve in the absence of a hysteresis
loop indicated a superparamagnetic behavior (Figure 3.5 B). A saturation magnetization
(Ms) of 9.36 emu/g was obtained from the curve.
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Figure 3.5 (A) Magnetic responsiveness of PVA-IONP microbeads upon introducing
of a permanent magnet close to the sample. The microparticles were attracted by
the magnet and would completely settle down due to gravity after the magnet was
removed. (B) Magnetic susceptibility of the microbeads. The absence of a hysteresis
loop indicates a superparamagnetic behavior of the PVA-IONP microbeads. The
saturation magnetization Ms of the microbeads was measured to be 9.36 emu/g.

3.3.4

MR Contrast Effect

As shown in Figure 3.6, a darkening effect was observed in the T2-wei
ghted images. An enhanced contrast against background was observed relative to a
control sample of neat PVA, thus confirming the effectiveness of iron oxide as a contrast
agent. In addition, a more prominent darkening effect was observed with a greater
amount of microbeads, indicating the contrast effect is correlated to the density of
microbeads hence the IONPs.
Control

1.56 mg
3.13 mg
microbeads in microbeads
phantom

6.25 mg
microbeads

50 mg
microbeads

Figure 3.6 T2-weighted MRI images of microbeads at different quantities (3T,
repetition time 350 ms, echo-time 3.5-15 ms). The white arrow indicates the
presence of PVA-IONP microbeads and their contrast effect on T2-weighted images.
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3.3.5

In vitro Degradation

Degradation of PVA-IONP microbeads was studied in DMEM at pH 7.4 and 5.5 for more
than 50 days. The degradation is measured quantitatively as iron release and qualitatively
as PVA matrix disintegration.
As depicted in Figure 3.7 A, iron release from microbeads appeared to be a two-stage
release with non-significant dependence on pH. Iron release rate remained slow at the
first stage (day 0-day 17), with less than 2.5% of total iron was released from microbeads
under both conditions. The release rate was faster at the second stage (day 18-day 52)
without reaching a plateau by the end of the measurements. After day 17, more than 20%
of total iron was released in 5 weeks, resulting in a ~26% cumulative release for
microbeads under acidic pH, while this number reached ~23% for samples under
physiological pH.
Due to the small value of the sample weight, we were not able to measure the weight loss
of the sample directly. However, the development of transparent beads (Figure 3.7 B and
C) revealed the release of IONPs, which can be taken as part of mass loss hence
degradation of PVA-IONP beads. In addition, SEM images of the beads at day 30 (Figure
3.7 D) showed changes in morphology, which confirmed the dissolution and
disintegration of the polymer matrix.
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Figure 3.7 Degradation of the PVA-IONP beads. (A) Cumulative iron released from
the microbeads. (B) and (C) are optical images of beads at day 0 and day 30,
respectively. (D) SEM micrograph of beads at day 30. Degradation study was
performed in DMEM at pH 5.5, 7,4 and 37 ℃. More than 20% of total iron was
released in 5 weeks for both conditions. The removal of IONPs can be further
visualized through the color change of the microparticles. The PVA-IONP
microparticles lost the original teardrop shape during the incubation. The release of
IONPs and disintegration of the polymeric matrix indicate the degradation of the
microbeads.
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3.3.6

DOX Loading and in vitro Release

Due to the abundant presence of hydroxyl groups in the PVA matrix, the microbeads are
anticipated to be capable of loading with hydrophilic drugs such as DOX, through van
der Waals interaction and hydrogen bonding [19]. The PVA-IONP microbeads allowed a
DOX loading capacity of 0.49 ± 0.02 mg/mL with a loading efficiency of 48.8 ± 2.5%.
As shown in Figure 3.8, a sustained and pH-dependent DOX release profile was observed
during the course of 7 days. For microparticles at pH 7.4, ~20% of DOX was released
within 1 hour and a maximum release of 32% was reached within 7 days. Acidic
environment significantly accelerated the DOX release such that ~33% of the drug was
released within the first hour and ~ 53% of Dox was released within a week.

Figure 3.8 Profiles of cumulative percent doxorubicin release with time from PVAIONP beads in PBS at pH 7.4, 5.5 and 37 ℃. The DOX loading was 0.49 ± 0.02
mg/mL with a loading efficiency of 48.8 ± 2.5%. Microparticles can provide a
controlled release for DOX for 7 days. Acidic environment contributes to a faster
and greater DOX release.
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3.4
3.4.1

Discussion
Fabrication of PVA-IONP Microparticles

Microfluidic fabrication was effective in producing PVA-IONP microparticles, resulting
in an equivalent spherical diameter of 95 ± 22 μm. In a flow-focusing geometry, at the
intersection, the central fluid (dispersed phase, PVA with IONP precursors) was
hydrodynamically flow focused by the fluid (oil phase, 1 wt.% Span80 in undecane) in
the two side channels. A pressure gradient along the long axis of the device forced two
liquids through the narrow orifice. Due to the wettability of the two phases to the
hydrophobic PMMA channel [20], only the oil phase can adhere to the channel wall,
hence the flow of the dispersed phase was pinched off by the oil phase to create droplets
[21,22], forming downstream water-in-oil droplets. These iron salts containing droplets
fell into the NaOH solution, which triggered the reaction shown in Equation 5, leading to
the formation of Fe3O4 nanoparticles inside the solidified PVA hydrogel microbeads.
These beads were further processed using the LTTC process to impart enhanced stability.
2FeCl3 + FeCl2 + 8NaOH ⟶ Fe3 O4 + 8NaCl + 4H2 O

(5)

Interestingly, the shape of the PVA-IONP microparticles was non-spherical. The initial
generation of non-spherical droplets was suspected to result from the viscous dispersed
phase. According to Nie et al. [23], for high viscosity liquids, the surface tension-driven
collapse of the neck at the last stage is slow, which would take longer for droplets to
break up. In addition, the planar design of the microchannel only allows quasi-2-D
contact of fluids. While fully shearing off the viscous disperse phase, the flow of disperse
phase was elongated into a teardrop shape due to the combined outcome of shear force
and viscoelastic effect [23–26]. Although the droplets would attempt to recover a
spherical shape in order to minimize the interfacial free energy after leaving the
microchannel [27], as the droplet fell into the NaOH solution, the combined forces
applied to the surface of the droplet (e.g., gravity, buoyancy, interfacial tension and drag
force), as well as the rigidity change induced by the co-precipitation, would preserve the
teardrop shape of the microdroplets [27].
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Apart from the shape, the size and size distribution of the microbeads must also be
considered. The equivalent spherical diameter of the beads was measured as 95 ± 22 m,
which size falls in the range of large arteries and capillaries [28,29]. For TACE therapy,
particles with a diameter smaller than 500 m would be desired [30], as they can be
easily administered by a catheter and reach the reach in close proximity to a tumor and
adequately occlude the vessels [12,31,32].
Despite the teardrop geometry, the PVA-IONP microparticles were fairly uniform in
shape with a reproducible size, making them suitable for serving as embolic agents. Some
irregularly shaped materials, such as ContourTM (Boston Scientific/Target Therapeutics,
USA) and Ivalon PVA blocks, have been used for artery embolization [33]. Although it
has been suggested that particles with uniform size and shape may reach more distal
locations and has a low probability to form proximal aggregates than irregular materials
or material with irregular shape [34–36]. Modifications to address the irregular shape can
be made by diluting dispersed phase to reduce the viscosity of the fluid, or by adopting a
3-D coaxial design for the flow-focusing channel [37].

3.4.2

Morphological, Elemental and Structural Features of
Microparticles

EDX confirmed the successful incorporation of IONPs into the PVA matrix. The size,
shape and dispersity of IONPs were further examined by TEM. IONPs formed were very
uniform in size with little or no aggregation (Figure 3.4 A). They were also found to be
distributed at the water-rich regions, adjacent to the interface of polymer-rich and waterrich regions. This type of distribution could be explained by the partition behavior of
IONP precursors between the two phases, as iron salts have higher solubility and
diffusivity in the aqueous phase (i.e., polymer-poor region) [15].
Size uniformity and good dispersity of IONPs are crucial factors as they govern the
magnetic behavior and the performance as a T2 contrast agent [39]. From the TEM
micrographs, the size of IONPs in the PVA matrix was 11± 2 nm with minimum
aggregation. IONPs at this size range are anticipated to be single domain particles hence
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behave superparamagnetically [40], which was confirmed by the VSM result (Figure 3.5
B).

3.4.3

Magnetic Properties

The magnetic property of PVA-IONP beads was confirmed by their movements towards
a permanent magnet, which indicated the potential application in magnetically-guided
drug delivery (Figure 3.5 A). Kumar et al. [28] were able to steer a group of
microparticles (D=200 m) with a cylindrical magnet (B=2T) in a simulated body fluid.
The beads can be propelled in parallel, antiparallel and angular directions in a linear
assembly. It is to be expected that these magnetic particles will be exposed to a more
complicated in vivo hydrodynamic environment where a combined effect of gravity, drag
force, magnetic force and intermolecular repulsive force will govern the locomotion of
particles [28,41]. However, with a deeper understanding of fluid dynamics and mechanics
and proper MRI gradient coil and designed algorithm, the particle trajectory can be
designed and controlled. For example, Chanu et al. [42] has successfully applied a
closed-loop control scheme and achieved automatic guidance of a single magnetic bead
(D=1.5 mm) in the carotid artery of a 25 kg living swine.
The superparamagnetic property of the PVA-IONP microparticles was evident from the
absence of coercivity and remanence magnetization, suggesting the in situ coprecipitation was effective in preparing superparamagnetic hydrogels. During the
reaction, the PVA network can potentially prevent agglomeration of IONP and makes it
low nanometer in size and well-dispersed [43]. In addition, PVA can serve as a stabilizer
to prevent Fe3O4 nanoparticles from exposure to O2, therefore prevent them from
oxidization [44].
A decrease in the Ms value (9.36 emu/g) compared to bulk magnetite (~90 emu/g) was
apparent [45]. This can be contributed by the reduced particle size of superparamagnetic
IONPs [46,47] and the dilution effect from adsorbed water and hydroxyl (-OH) content
[45]. Also, the PVA matrix could act as a dead layer to restrict the magnetic coupling
interaction and diminish the net moment, resulting in a reduction in Ms [48,49].
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Taken all together, the development of superparamagnetic microparticles is useful in
magnetic field-related applications such as magnetically-guided drug delivery. These
particles can follow the pre-designed route to reach the targeted site through a fine spatial
control [50]. This superparamagnetic property can potentially be helpful in MRI, as it can
filter background effects of biological paramagnetic materials (e.g., deoxymyoglobin and
deoxyhemoglobin) to obtain images with better contrast [51].

3.4.4

MR Contrast Effect

With an increased IONPs weight in the sample, a darkening effect in T2 image was
observed as expected. It was reported by Wabler et al. [52] that T2-weighted contrast
positively correlated with a total iron concentration in the samples, this can be understood
that the transverse proton relaxation rate (R2) increased with an increased IONP
concentration due to the signal dephasing effects of magnetic nanoparticles [53–55].
The detectability of beads will be extremely helpful in clinical practice to address the lack
of feedback during DEB-TACE procedure [56]. The distribution of beads can provide a
real-time location to guide the intervention. More importantly, since the drugs and the
IONPs are co-localized in the microbeads, the location of beads can serve as a surrogate
to report on local drug concentrations.

3.4.5

In vitro Degradation

It was found that negligible iron content (less than 2.5%) was released in the first 17
days, indicating a strong binding between the IONPs and PVA (Figure 3.7 A). The
relatively faster release in the following weeks could be a result of fast dissolution and
diffusion of IONP at the outmost layer of the gel beads [19]. However, this iron release
profile could still be helpful in TACE therapy, as imaging is usually required after 2-7
days and 3-6 weeks after the first treatment to assess the tumor response [57]. This IONP
release rate can potentially provide sufficient amount of IONPs for each imaging session
[4,57,58].
It is worth noting that the pH effect on IONP release was not significant, which may be
caused by the complex nature of such a process. In this regard, we hypothesized that
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IONP release from swellable hydrophilic PVA matrix could be contributed by a series of
physical and chemical process, involving liquid penetration into the polymer network, the
hydration and swelling of PVA matrix, dissolution reaction, solubilized iron content
diffusion throughout swollen matrix and, possibly with, the degradation of polymer
matrix [59]. Among all the processes, the diffusion process can be rate-controlling.
Therefore, all IONPs accessed by HCl can be reacted and converted to soluble iron salts
within the sampling interval. However, dissolved iron content was retained in the PVA
hydrogel and diffused into the medium at a pace determined by the diffusivity, hence the
degradation of the polymer matrix [60].
In our previous study on the PVA-IONP bulk material, we have demonstrated the
removal of iron mechanically weakens the hydrogel and contributes to the total mass loss
of the sample [16]. The authors hypothesized that the stability of the hydrogel was
provided by the IONP crosslinking and the physical crosslinking by the LTTC process.
The degradation of the material can be regarded as the total mass loss of the hydrogel
contributed by the loss or release of iron and the material dissolution.
In this study, the release of IONPs was quantified by the AAS. The SEM observation
(Figure 3.7 D) provided qualitative evidence. The shape loss and polymer matrix
disintegration were clearly observed on the microparticles at day 30, indicating the
degradation of PVA-IONP microbeads.
Degradable materials could be advantageous in tumor embolization as they provide
transient embolic effects, which can potentially prevent the occurrence of the postembolization syndrome, tissue inflammation and fibrosis, and risks from non-target
embolization [13,14]. Particularly for patients with HCC, it is reported that over 90% of
patients need repeated treatments. As such, degradable microparticles would ideally
permit multiple TACE procedures hence better treatment outcomes [33].

3.4.6

DOX Loading and in vitro Release

The PVA-IONP microbeads supported sustained DOX release at pH 7.4 and pH 5.5, and
the trend suggested the drug release was pH-responsive. The released anticancer drug
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contents reached 51.0 ± 2.2% by 7 days, almost 1.6 times of the release at healthy
physiological pH. This greater release may be resulted from the protonation of the
primary amine groups (-NH2) of DOX under an acidic environment, depriving the sites
available for hydrogen bonding with PVA.
The microparticles developed incomplete DOX release at both pH conditions, indicating
the solute release may be controlled by hydrogen bonding and degradation of
microparticles. Taken the degradation measurements together, it is likely that the slow
degradation of PVA contributes to the incomplete release of DOX. Nevertheless, the
DOX release was in a controlled manner for one week, which could potentially result in a
more significant impact on tumor kill.

3.5

Conclusion

This work successfully synthesized novel composite hydrogel microbeads using
microfluidic fabrication and in situ co-precipitation for IONP synthesis within the PVA
matrix. The resulting drug delivery systems were in a teardrop shape with a relatively
narrow size distribution. The microparticles exhibited superparamagnetic properties and
were effective in producing a contrast-enhancing effect on MR images. Such properties
also suggest the feasibility of magnetically-guided drug delivery and in vivo imaging
during/post the intervention. Moreover, PVA-IONP microparticles were degradable,
allowing repeatable TACE to be applied. Degradation occurred in the form of iron release
and matrix disintegration. Moreover, these microparticles acted as a suitable carrier for
DOX and rendered a controlled release for a course of one week. All these outstanding
characteristics make PVA-IONP microparticles an improved DEB system in TACE
therapy.

3.6
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Chapter 4

4

Development of a Multifunctional Bioactive
Protein/Peptide Delivery System for Dry Eye Disease2
4.1

Introduction

Dry eye disease (DED) is a multifactorial disease characterized by inflammation that
damages the ocular surface and tear producing glands [3,4]. Tear film instability or
osmolarity changes, among others, stress underlying corneal epithelial cells, inducing
further release of pro-inflammatory cytokines, including interferon-γ (IFNγ) and tumor
necrosis factor (TNF) [3,5,6]. All severities of DED substantially reduce health-related
quality of life [7]. Worldwide prevalence is estimated at 5.5–33.7% with Canada at 25%,
but underestimates may result from patients’ failure to recognize or report symptoms,
indicating a large public health issue [4,8].
Eye drops are widely used to deliver artificial tears and anti-inflammatory agents to the
ocular surface of DED patients [5]. This method fails to sustain drug delivery, with less
than 5% of the topically applied drug dose reaching target corneal tissue. Rapid drug
elimination can be attributed to blinking, the tear film barrier, reflex tearing, and drainage
through tear ducts [9]. Losing over 95% of the formulation’s dose during drug delivery
not only impairs cost-effectiveness but also requires diligent patient compliance with
frequent dosing throughout the day to maintain adequate efficacy within target tissues.
Such high patient compliance is not consistently attainable, likely decreasing therapeutic
effectiveness.
Current pharmaceutical agents commonly used to treat DED are also unfavorable as longterm solutions. Artificial tears provide only temporary lubrication without addressing the
underlying pathology of DED, with most formulations lacking bioactive tear components
[10,11]. Long-term use of corticosteroid eye drops may increase the risk of developing

2

A version of this chapter will be submitted to Clinical & Experimental Ophthalmology under the title:
Lacritin peptide (N-94)-conjugated solid silica nanoparticles as a novel drug delivery system for dry eye
disease. Xinyi Li shares the co-first authorship with Angela Chang.
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glaucoma, cataracts, and bacterial infections [3,5,10]. Prolonged use of cyclosporine can
lead to complications such as lid maceration and corneal epitheliopathy [12]. Indeed, few
physicians in White et al.’s study were satisfied with the ability of cyclosporine and
lifitegrast to manage DED symptoms and improve quality of life [13].
The development of protein and peptide-based therapeutics is rapidly increasing for the
treatment of a wide variety of clinical indications [14]. Inorganic nanoparticles such as
gold nanoparticles (AuNPs), iron oxide NPs (IONPs), and silica NPs (SiNPs) have also
been extensively investigated. They are highly biocompatible, with some formulations
proceeding to the clinical trial stage [15]. Among these, SiNPs are especially promising
as carriers for ophthalmic therapeutics to overcome the bioavailability limitation of
traditional eye drops. Generally Recognized as Safe (GRAS) by the FDA, SiNPs are
generally not cytotoxic to human corneal epithelial cells (HCECs), with larger diameters
having a lower risk of cytotoxicity [16–18]. Lysozyme is widely used in the study of
silica-protein interactions due to its conformational stability and similar properties to
numerous bioactive proteins [19,20]. In addition to its prototypical features, lysozyme
possesses antimicrobial, anti-inflammatory properties and is also a major component of
the tear film [21–23].
Lacritin has many desirable properties conducive to its development as a therapeutic
agent for DED. It is a human tear glycoprotein secreted by the lacrimal glands and
downregulated in DED tears [24,25]. Topical application enhances basal tearing in
rabbits [10,26]. It is mitogenic and cytoprotective on HCECs in vitro [27,28]. Its Cterminus is bactericidal and rescues HCECs stressed by inflammatory mediators IFNγ
and TNF by stimulating an autophagy pathway to clear damaged organelles and proteins
[29–31]. Because its C-terminus has a heparanase-dependent binding mechanism to
syndecan-1, lacritin binding targets areas of the eye highly associated with DED [32,33].
Since lacritin’s C-terminus mediates receptor activation and thus prosecretory,
bactericidal, and cytoprotective activity, the N-94 fragment should be equipotent to the
complete protein. We investigated a synthetic 25-amino acid lacritin peptide (N-94)
derived from lacritin’s C-terminal side as a candidate drug to be delivered by SiNPs. N-
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94 is smaller and has a more suitable isoelectric point than lacritin, maximizing its
loading potential onto SiNPs. Preliminary studies indicate that N-94 has a predicted
isoelectric point (IEP) of 10.5 while lacritin has an IEP of 5 [34]. At physiological pH, N94 would be positively charged to aid in its adsorption to the negatively charged SiNP
surface [35].
The use of SiNPs as a controlled release delivery system for the N-94 offers several
advantages for the treatment of DED. Since the N-94 fragment decomposes readily on the
inflammatory and oxidative ocular surface, the N-94-SiNPs would allow for sustained
availability of N-94 over time [2]. Furthermore, the loading, release time profile, and
dosage can be tuned based on clinical needs.
While an existing study found that lacritin reduces HCEC death induced by proinflammatory cytokines, it was unconfirmed whether N-94 had similar cytoprotective
effects [29]. The biocompatibility of N-94 and N-94-conjugated SiNPs (N-94-SiNPs)
with HCECs was also yet to be elucidated.
In is study, we synthesized the SiNPs using the Stöber method. Their drug loading and
controlled release properties were characterized using lysozyme as a model protein.
Dissolution of the SiNPs was also demonstrated. N-94 was subsequently conjugated to
SiNPs, its release profile, presence of toxicity to HCECs, and cytoprotective activity were
also studied to assess the feasibility of the conjugated system for treating DED.

4.2
4.2.1

Materials and Methods
Materials

All chemicals were used as received without further purification. Tetraethylorthosilicate
(TEOS, 99+%) and lysozyme from chicken egg white (minimum 23,500 units/mg
protein) were purchased from Alfa Aesar, ammonium hydroxide (28%-30% NH3 in H2O)
was obtained from Caledon. Phosphate buffered saline tablets and dimethylsulfoxide
(DMSO) were purchased from Sigma-Aldrich. Ethanol (95%) was obtained from
Commercial Alcohols. Inflammatory cytokines IFNγ and TNF were acquired from
Thermo Fisher Scientific. Peptide N-94 was obtained from GenScript (Piscataway, NJ),
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custom-made with fluorescein isothiocyanate (FITC) and a seven-atom aminohexanoyl
spacer covalently conjugated to the peptide’s N-terminus to allow for quantification via
fluorescence spectrophotometry. Distilled water was used for all experiments.

4.2.2

Preparation and Characterization of Protein/Peptide-SiNPs
Conjugates

SiNPs were synthesized by the Stöber method [217]. In a typical synthesis, solution
containing 5 mL ethanol and 10 mL ammonia was prepared. After equilibration at room
temperature (23  1C), 100 L TEOS was added dropwise and the reaction was
maintained at the same temperature for 1 hour under constant stirring. The resulting white
precipitate was separated by centrifugation (Sorvall RC5C, Sorvall Instruments, USA),
washed with water and ethanol, and dried at 60 C under vacuum overnight for future
use.
To prepare lysozyme loaded SiNPs for characterization, conjugates were prepared from a
relatively concentrated lysozyme solution (10 mg/mL, 1 mL) and 15 mg SiNPs. To load
N-94 onto the SiNPs, a 20:1 ratio (w/w) of SiNP:N-94 each suspended in equal volumes
of PBS were combined in Eppendorf tubes. Adsorption was allowed for 48 hours at room
temperature for both formulations. Pellets were separated and rinsed with PBS to remove
loosely attached lysozyme molecules. FTIR (Bruker Vector, USA) and scanning electron
microscopy (SEM, LEO1540XB FIB/SEM, ZEISS, USA) were performed on both airdried bare SiNPs and protein/peptide-SiNPs conjugates.

4.2.3

Protein Adsorption Kinetics and Isotherms

For the adsorption kinetics studies, lysozyme-SiNP conjugates were prepared by mixing
100 mg of SiNPs in a beaker containing 12 mL of a 0.5 mg/mL lysozyme in 1x PBS
solution (pH 7.4). Adsorption was performed at room temperature in an orbital shaker
(New Brunswick Scientific) at 75 rpm. All experiments were performed in triplicate.
At pre-determined time points, 0.5 mL supernatant was retrieved. Lysozyme
concentration in the supernatant was determined by a Cary UV-vis spectrophotometer
(Agilent Technologies) at =280 nm.
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The amount of lysozyme adsorbed onto SiNPs at time t, Q t was determined by the
concentration difference between the stock solution and supernatant:
Qt =

(C0 − Ce )V
m

(1)

where C0 and Ct are the concentration of lysozyme in the stock solution and in the
suspension at time t (mg/L), respectively. V is the total volume of the solution (in L), and
m is the weight of SiNPs (g).
Isotherm studies were performed with a constant dosage of SiNPs (15 mg/mL in the final
mixture) and varying concentrations of lysozyme (C0 ) in the range of 133 mg/L to 3000
mg/L. The mixture was shaken at 160 rpm for 48 h at ambient temperature. Finally,
samples were centrifuged for 5 minutes at 8,000 rpm to retrieve supernatant, which was
subject to UV-vis for lysozyme quantification.

4.2.4

Protein/Peptide Release in the Absence of Cells

The release of bioactive protein/peptide from SiNPs were characterized using lysozyme
and N-94 as the prototypical molecules. Lysozyme-SiNP and N-94-SiNP conjugates were
prepared separately by mixing SiNPs and corresponding adsorbates at a 20:1 ratio (w/w).
Adsorption was maintained at room temperature in an orbital shaker at 75 rpm for 48
hours. The resulting conjugates were rinsed with PBS and transferred to microcentrifuge
tubes (Sigma-Aldrich) containing 1 mL PBS in each. Release was then carried out at
37C in the orbital shaker at 75 rpm. At pre-determined time points, supernatant was
replaced with fresh PBS to maintain the total volume constant.
The amount of adsorbed/released adsorbates was determined by UV-vis in the case of
lysozyme, while for N-94 quantification, a SpectraMax M3 Multi-Mode Microplate
Reader (Molecular Devices, LLC, CA) was used. Samples were excited at 496 nm and
emission intensity at 520 nm was acquired. In addition, matrix assisted laser desorption
ionization-time of flight mass spectrometry (MALDI-TOF MS) was used to verify the
integrity of pre-conjugated and released N-94 samples obtained at 8 hours, suspended in
ultrapure water. Samples were mixed at a 1:1 ratio (v/v) with an α-cyano-4hydroxycinnamic acid MALDI matrix (5 mg/mL in 50% acetonitrile and 0.1%
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trifluoroacetic acid) and spotted on the MALDI plate in duplicates. MS data were
obtained using an AB Sciex 5800 TOF/TOF System (Framingham, MA). Data
acquisition and processing were done using an AB Sciex TOF/TOF Series Explorer and
Data Explorer.

4.2.5

Dissolution of SiNPs in the Absence of Cells

In vitro degradation was studied in PBS at 37C with SiNPs alone. Typically, 10 mg of
SiNPs were added into 5 mL of PBS and samples were incubated in a shaker at 75 rpm.
PBS was replaced every 5 days to prevent solution saturation. At pre-determined time
points, solid SiNPs were retrieved, washed, and resuspended in water. Transmission
electron microscopy (TEM, PhillipsCM10) graphs were taken to examine the structural
changes of SiNPs during the degradation. TEM samples were prepared by dropping this
suspension onto a Formavar carbon-coated copper grid.

4.2.6

Cell Culture

Primary human corneal epithelial cells (HCECs) obtained from three different donors
were purchased from American Type Culture Collection (ATCC, Manassas, VA).
HCECs at the second passage at the time of purchase were cultured in colorless,
keratinocyte-serum free Corneal Epithelial Cell Basal Medium with Corneal Epithelial
Cell Growth Kit supplements (ATCC). For all experiments, cultured cells were seeded in
24-well plates directly into the wells or into trans-well inserts at a density of 2×105
cells/cm2 and treated when 80% confluent.

4.2.7

Determination of Optimal Pro-inflammatory Cytokines IFNγ &
TNF Concentration

Using Wang et al.’s study as a guideline, a fixed IFNγ concentration of 100 U/mL was
combined with varying concentrations of TNF to insult HCECs for 16 or 20 hours [29].
The combination that reduced cellular metabolic activity from 100% to about 65–75%
was used to stress HCECs. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used to measure cellular metabolic activity.
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4.2.8

Effects of N-94 on HCECs

Effect of N-94 on HCECs was evaluated in terms of cytotoxicity and cryoprotection. To
detect potential cytotoxicity, HCECs were treated with 1–10 000 nM of N-94 for 1–24
hours. Cells cultured in medium without the addition of N-94 were used as negative
controls (“vehicle control”).
At designated times, cell viability was determined by the measurement of cellular
metabolic activity using the MTT assay. Briefly, cells were incubated in 24-well plates in
serum-free conditions with 450 μg/mL MTT solution (Sigma-Aldrich) for 3 hours at
37oC. After aspirating excess MTT, dimethylsulfoxide (DMSO, Sigma-Aldrich) was
added and plates were shaken. Samples were transferred to 96-well plates in triplicate,
with a few wells reserved for DMSO only. Absorbances were read at 575 nm by the
iMark Microplate Reader (Bio-Rad Laboratories). The DMSO absorbance was subtracted
from all other absorbances. The cellular metabolic activity of experimental groups was
normalized by the vehicle control group (100%) in all cellular studies and expressed as
percentages.
To investigate the cytoprotective effects of N-94 on HCECs, HCECs were
simultaneously treated with 1–10 000 nM of N-94 and pro-inflammatory cytokines of the
optimal concentration combination for 16 and 20 hours. The positive control consisted of
HCECs stressed by cytokines in the absence of N-94 (“insult only”). The negative control
was untreated, healthy HCECs incubated in cell medium only (“vehicle control”). The
MTT assay was performed to determine cellular metabolic activity.

4.2.9

Effect of N-94-SiNPs on HCECs

Cytotoxicity and cytoprotective effect of the complete delivery system (i.e., N-94-SiNPs)
on HCECs were assessed. N-94-SiNPs were prepared as per section 2.4 in concentrations
of 5.6–5600 nM. Based on preceding experiments, it was assumed that 90% is adsorbed
and 40% is maximally released, along with a 50% dilution during treatment, yielding
final treatment concentrations of 1–1000 nM. Release of N-94 was conducted in a water
bath shaker at 37 oC for 8 hours. The resulting mixtures were vortexed and used as the
treatments.
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N-94-SiNPs treatments were then performed in a non-contact manner. HCECs were
cultured in trans-well inserts (0.4 µm pores, Falcon, Canada) placed into compatible 24well plates. Each well contained treatment basolateral to the cells and cell culture
medium apical to the cells. The controls were cell culture medium with PBS only
(“vehicle control”) and SiNP treatment only.
At designated times, cells in the culture inserts were subjected to the MTT assay, while
apical and basolateral supernatants were combined from each well and subjected to the
lactate dehydrogenase (LDH) assay. LDH standards were prepared and loaded with
supernatant samples in triplicate into 96-well plates. Reaction solution was prepared
using an LDH assay kit (Sigma-Aldrich) then added to each sample and standard. Plates
were incubated for 10 minutes at 37 oC and absorbances were read using a dual filter at
490 nm and 655 nm by the iMark Microplate Reader. LDH concentrations were
calculated using the standard curve. LDH release of experimental groups was normalized
by the vehicle control group (100%) and expressed as percentages.
To evaluate the cytoprotective property of released N-94, N-94 loading and release were
performed as per section 4.2.4. After release was complete, tubes were centrifuged and
supernatant samples containing the released N-94 were extracted as the treatment.
HCECs were then co-treated with 100 U/mL of IFNγ and 12.5 ng/mL of TNF and 1–
1000 nM of released N-94 in PBS for 16 and 20 hours. The controls were cell culture
medium with PBS only (“vehicle control”) and cytokine insult only (“insult only”).
Afterwards, apical supernatants were collected and analyzed using LDH and MTT
assays.

4.2.10

Statistics

A one-way analysis of variance (ANOVA) was performed on the diameter of the silica
nanoparticles using OriginLab 2019b (OriginLab Corporation, MA). For protein/peptide
release and biological studies, three biological replicates (i.e., cell lines from distinct
donors) and three technical replicates of each cell line were performed for each cellular
experiment. GraphPad Prism v8.01 (La Jolla, CA) was used to conduct one- and two-way
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ANOVAs and post-hoc tests. Values of P < 0.05 were considered statistically significant.
All results are reported as the mean ± standard deviation.

4.3
4.3.1

Results
Preparation and Characterization of Protein/Peptide-SiNPs
Conjugates

SiNPs were synthesized using a Stöber procedure [36]. The product nanoparticles were
characterized in terms of their morphology, size, and size distribution. The SEM
micrograph in Figure 4.1 A shows that the SiNPs are spherical and non-porous with a
fairly uniform size and minimum aggregation. Uniformity of the SiNPs’ size was
confirmed by the narrow size distribution shown in the insert. The average diameter was
determined to be 251  19 nm. In the N-94 study, a new batch of SiNPs with good size
uniformity (374 ± 15 nm) was prepared and used (Figure 4.1 B). Particle size can be
tuned by varying a combination of reaction time, temperature and reactants ratio [37].

Figure 4.1 SEM of SiNPs used in (A) lysozyme and (B) N-94 study. Insert is the
particle size distribution.
Lysozyme and N-94 molecules were conjugated to the SiNPs by batch adsorption. The
adsorption of such molecules onto the surface of the SiNPs is visible (Figure 4.2 A).
Lysozyme loading was further confirmed by FTIR. The absorption band at ~1650 cm-1 in
the FTIR spectrum corresponds closely to the amide I peak for proteins [38]. the major
band for silicon dioxide is located at ~1077 cm-1. As seen in Figure 4.2 B, the peptide N-
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94 was also successfully conjugated onto the SiNPs. The amount of N-94 conjugated was
too small for FTIR analysis. However, characterization of the N-94 recovered in
controlled release experiments shown in Figure 4.4 D serves as indirect evidence of
loading success.

Figure 4.2 (A) SEM of lysozyme-loaded SiNPs. The red arrow indicates the presence
of lysozyme. Insert: FTIR spectrum of SiNPs, lysozyme powder and lysozymeSiNPs. The red arrow indicates the characteristic bands of proteins, and the black
arrow indicates the characteristic bands of silica. (B) SEM of N-94-loaded SiNPs.
The SEM micrographs and FTIR spectrum confirm the loading of lysozyme and N94 onto the SiNPs surface.

4.3.2

Adsorption Kinetics and Isotherms

To better understand the adsorption mechanism, kinetic data was analyzed using pseudofirst-order and pseudo-second-order models, according to ref. [39]
Pseudo-first-order kinetic:
log(Q e − Q t ) = logQ e −

k1 t
2.303

(2)

Pseudo-second-order kinetic:
t
1
t
=
+
Q t k 2 Q2e Q e

(3)
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where Q e (mg/g) represents the amount of lysozyme being adsorbed at equilibrium. k1
(h−1 ) and k 2 (g·mg-1·h-1) are the rate constants of pseudo-first- and second- order
adsorption respectively.
Time dependent adsorption data was collected for up to 72 hours at room temperature (23
 1 oC). Results are shown in Figure 4.3 A. Kinetic data is found to be best fitted to the
pseudo-second order model (𝑅2 > 0.99). The parameters, Q e and k 2 , derived for
Equation 3 were determined to be 34.97 mg/g and 0.012 g·mg-1·h-1 respectively, the
calculated adsorption time course curve is also shown in Figure 4.3 A, demonstrating the
validity of the kinetic model.
Isotherm data were fitted into Freundlich and Langmuir models. The linearized forms of
these two models are shown in below [39,40]:
Freundlich isotherm:
1
logQ e = logk f + logCe
n

(4)

where Ce is the equilibrium concentration of lysozyme (mg/L) in the solution, and k f
(mg/g) and n are the Freundlich isotherm constants related to adsorption capacity and
intensity respectively.
Langmuir isotherm:
Ce
Ce
1
=
+
Qe Qm Qm b

(5)

where Qe (mg/g) is adsorbed lysozyme at equilibrium, Q m (mg/g) is the maximum
adsorption amount at complete monolayer coverage, and b (L/mg) is the Langmuir
constant representing the energy of adsorption.
Fitting results are shown in Figure 4.3 B. Among the two adsorption isotherm models, it
was found that the data fit well with the Langmuir model (R2=0.94) as shown by the line
in Figure 3B. The fitting parameters for the Langmuir isotherm were determined to be
Qm=76.34 mg/g, b=0.0026 L/mg. The complete fitting parameters and curves for
adsorption kinetics and isotherms can be found in Appendix D.
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Figure 4.3 (A) Adsorption kinetics and (B) isotherm at 296 K. Error bars for some
data points are too small to be displayed. The black square shows the experimental
data, and the red dash curve shows the best-fit curve. Kinetic data is fit with
pseudo-second order kinetic (R2 > 0.99). Isotherm data fits well with the Langmuir
isotherm (R2 = 0.94).

4.3.3

Protein/Peptide Release in the Absence of Cells

SiNPs provided controlled release for both lysozyme and N-94 over the course of 8
hours. Approximately 50% of the loaded lysozyme was released within the first 3 hours
with complete release from SiNPs within 24 hours (Figure 4.4 A). N-94 exhibited a
similar release profile (Figure 4.4 B). ~30% release was achieved within the first 3 hours,
while a plateau was reached after 8 hours, where ~45% of the total loaded N-94 was
released.
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(A)

(C)

(B)

(D)

Figure 4.4 (A) Lysozyme release from SiNPs in PBS at pH 7.4 and 37 ℃ in the
absence of cells. Lysozyme loading (i.e., 𝑴∞ ) was 21.74 ± 2.32 mg/g. (B) N-94 release
from SiNPs, N-94 loading (i.e., 𝑴∞ ) was 44.94 ± 0.42 mg/g. SiNPs can providde
controlled release for both lysozyme and N-94 over the course of 8 hours.
Representative spectra of various masses (m/z or Da) of lacritin peptide (N-94) (C)
prior to its conjugation to SiNPs, and (D) after release from SiNPs. The conjugation
to SiNPs and release do not affect peptide integrity.
The integrity of N-94 was maintained throughout its release. MALDI-TOF mass
spectrometry of pre-conjugated N-94 (Figure 4.4 C) as well as N-94 that was released
after being conjugated to SiNPs (Figure 4.4 D) revealed high intensity peaks of the full
25-amino acid long peptide, both with FITC at 3400 Da and without FITC at 3000 Da.
There were no peptide fragments of less than 3000 Da in either spectrum, indicating that
conjugation to SiNPs does not affect peptide integrity.
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4.3.4

Dissolution of SiNPs in the Absence of Cells

SiNPs degradation was studied under physiological conditions in PBS for up to 30 days.
Progress of the degradation process was monitored in terms of SiNPs diameters as a
function of time using TEM (Figure 4.5). Results for Days 0, 10 and 30 were found to be
113 ± 15 nm, 103 ± 20 nm and 98 ± 15 nm, respectively. One-way ANOVA confirmed
that the size reduction of SiNPs was statistically significantly over the period of the
experiment (P < 0.05).
(A)

(B)

(C)

(D)

*
*

Diameter (nm)

150

100

50

Day 0

Day 10

Day 30

Figure 4.5 SEM images of SiNPs with an increasing immersion time in PBS, (A) t=0,
(B) t=10 days, and (C) t=30 days. (D) Size variation of SiNPs after immersion in PBS
for 0, 10, and 30 days. Each value is presented as mean ± SD. Based on the one-way
ANOVA test, size of SiNPs significantly decreased with a prolonged immersion time
(*, P < 0.05), indicating the degradation of the nanoparticles.

4.3.5

Toxicity of N-94 to HCECs

Toxicity of N-94 to HCECs was examined over a N-94 concentration range of 1–10 000
nM for up to 24 hours and measured using cellular metabolic activity. Exposure of HCEC
to N-94 up to the maximum peptide concentration and exposure time used did not result
in significant changes in cellular metabolic activity (Figure 4.6).
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Figure 4.6 Mean cellular metabolic activity (% relative to vehicle control ± SD) of
primary human corneal epithelial cells obtained from three donors (N=3) following
treatment of lacritin peptide (N-94) (1, 10, 100, 1000, 10 000 nM). Vehicle control
(dotted line, 100%) was cell culture medium treatment only. MTT assays were
performed after 1, 2, 6, and 24-hour treatment durations. There were no significant
differences in cellular metabolic activity between the varying concentrations and
durations of N-94 treatment, including vehicle control.

4.3.6

Cytoprotective Effects of N-94 to HCECs

The concentration of pro-inflammatory cytokines used to insult cells were first optimized
to decrease cellular metabolic activity to 65–75% of that of “healthy” vehicle control
cells to test the cytoprotective effects of N-94 (Figure 4.7 A). Treatment of HCECs with
an insult combination of 100 U/mL IFNγ and 12.5 ng/mL TNF for 16 and 20 hours
respectively decreased cellular metabolic activity to 74.80 ± 6.25% and 66.09 ± 1.92%.
HCECs insulted with the optimized concentrations of IFNγ and TNF were co-treated with
N-94 (Figure 4.7 B). Compared to insult only by IFNγ and TNF, there were significant
increases in cellular metabolic activity when co-treated with 1 nM (P < 0.05) or 10 nM (P
< 0.001) of N-94 after 20 hours. The effect of co-treatment with 100 nM and 1 000 nM
N-94 on insulted HCECs were statistically non-significant. However, treatments of 10
000 nM of N-94 at 16 and 20 hours significantly (P < 0.01) decreased cellular metabolic

120

activity in comparison to insult only. This higher N-94 concentration was removed from
the subsequent experiments that tested with N-94-SiNPs.

Figure 4.7 . Mean cellular metabolic activity (% relative to vehicle control ± SD) of
primary human corneal epithelial cells obtained from three donors (N=3) following
(A) insult by 100 U/mL of IFNγ and varying concentrations of TNF (0, 6.25, 12.5, 25,
50, 100 ng/mL) and (B) co-treatment of lacritin peptide (N-94) (0, 1, 10, 100, 1000,
10 000 nM) along with insult by 100 U/mL IFNγ and 12.5 ng/mL TNF. In both,
vehicle control (dotted line, 100%) was cell culture medium treatment only. MTT
assays were performed after 16- and 20-hour treatment durations. *, **, and ***
indicate statistical significance versus insult only. ***, P < 0.001; **, P < 0.01; *, P <
0.05.
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4.3.7

Toxicity of N-94-SiNPs to HCECs

HCECs were treated with the mixture containing SiNPs, released N-94, and any potential
dissolution products of SiNPs. Statistical analysis showed no significant differences in
cellular metabolic activity between treatments of any concentration of N-94-SiNPs up to
1 000 nM or SiNPs and vehicle control at 16 and 20 hours (Figure 4.8 A). There were
also no significant differences in LDH release between treatments of any concentration of
N-94-SiNPs up to 1 000 nM or SiNPs and vehicle control at either time point (Figure 4.8
B).
(A)

(B)

Figure 4.8 (A) Mean cellular metabolic activity (% relative to vehicle control ± SD)
and (B) mean lactate dehydrogenase (LDH) release (% relative to vehicle control ±
SD) of primary human corneal epithelial cells obtained from three donors (N=3)
following treatment of lacritin peptide-conjugated silica nanoparticles (N-94-SiNPs)
(1, 10, 100, 1000 nM). There was a vehicle control (dotted line, 100%) of phosphatebuffered saline and cell culture medium treatment only and a group of bare SiNP
treatment only. MTT and LDH assays were performed after 16- and 20-hour
treatment durations. There were no significant differences in cellular metabolic
activity and LDH release between the various treatments and vehicle control at
either time point.
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4.3.8

Cytoprotective Effect of Released N-94 on Stressed HCECs

Compared to insult only, treatment equivalent to 1 nM of released N-94 significantly (P <
0.05) increased the cellular metabolic activity of insulted cells at 16 and 20 hours while
10 nM of released N-94 significantly (P < 0.001) increased the cellular metabolic activity
of insulted cells at 20 hours (Figure 9A). Compared to insult only, co-treatment with 10
nM (P < 0.01) and 1000 nM (P < 0.05) of released N-94 significantly reduced the LDH
release of HCECs at 20 hours (Figure 4.9 B).

(A)

(B)

Figure 4.9 (A) Mean cellular metabolic activity (% relative to vehicle control ± SD)
and (B) mean lactate dehydrogenase (LDH) release (% relative to vehicle control ±
SD) of primary human corneal epithelial cells obtained from three donors (N=3)
following co-treatment of lacritin peptide (N-94) (0, 1, 10, 100, 1000 nM) released
from silica nanoparticles along with 100 U/mL IFNγ and 12.5 ng/mL TNF. Vehicle
control (dotted line, 100%) was phosphate-buffered saline and cell culture medium
treatment only. MTT and LDH assays were performed after 16- and 20-hour
treatment durations. *, **, and *** indicate statistical significance versus insult
only. ***, P < 0.001; **, P < 0.01; *, P < 0.05.
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4.4

Discussion

The Stöber process provides a facile pathway towards the synthesis of fairly uniform
SiNPs using the silica precursor TEOS [36]. Uniformity in size (Figure 4.1) allows for
precise drug loading. SiNP size can be tuned as a function of reaction pH and
temperature. SiNPs in the size range of 100-400 nm are promising for drug delivery
applications, as they render a sufficient surface area to volume ratio to enable a high
loading and would not induce significant cytotoxicity [16].
Lysozyme loading onto SiNPs is demonstrated by both SEM and FTIR. Aggregation of
lysozyme can be seen which has been attributed to lysozyme-SiNP interaction on the
particle surface [41]. Lysozyme conjugation to SiNPs is further confirmed by the FTIR
spectrum (inset, Figure 4.2 A). For lysozyme, the amide I peak intensity is low at 1649
cm-1, likely due to its low concentration relative to the SiNPs, but its presence serves as
direct evidence of successful conjugation of lysozyme to SiNPs [42]. The amide II peak
at 1550 cm-1 was not observed due to its lower intensity compared to the amide I peak
[43].
Results of adsorption experiments over a 72-hour period are shown in Figure 3A. The
results indicated that equilibrium adsorption was attained at around 45–50 hours. At the
early stage (0–12 hours), adsorption was fast due to the high concentration of lysozyme
and the number of binding sites. As adsorption proceeded, the rate slowed down, possibly
due to the depletion of lysozyme and occupation of binding sites [40].
Pseudo-second order kinetics suggests that chemisorption is the rate controlling step
throughout the adsorption process [44], the adsorption of lysozyme on SiNPs is most
likely a combined effect of both physical and chemical interactions.
Equilibrium loading capacity is an important parameter in assessing the suitability of
SiNPs as a carrier for the controlled release of a protein for therapeutic applications as it
can be used to determine the maximum loading capacity for the release of a protein
within the therapeutic dose range by a carrier. Among the several models available, the
Langmuir model was found to be the best to describe the experimental data (R2 = 0.94)
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[41,45,46]. This adsorption isotherm assumes monolayer adsorption with minimal
interaction among the adsorbate molecules. With macromolecular proteins such as
lysozyme with surface functional groups, the process is more complex. The difference
IEPs between SiNPs (IEP ~3.0) and lysozyme (IEP=10.9) would lead to the adsorption of
positively charged protein onto SiNPs, resulting a protein monolayer on the surface
SiNPs [38,47]. The existence of intermolecular repulsive electrostatic interactions will
prevent second layer of adsorption. The maximum monolayer adsorption capacity (Q m)
of lysozyme on silica nanoparticles typically falls in the range of 50-520 mg/g, depending
on the pH and ionic strength, with the greatest Qm achieved at a pH near the IEP of
lysozyme in the absence of electrolyte [46,48]. The deviation from this maximum loading
could be explained by the salts in PBS and the suboptimal loading pH.
The release process of cargo is governed by the concentration gradient of the
protein/polypeptide at the SiNPs surface followed by its rapid diffusion into the medium
(Figure 4.4 A and B). This type of release profile makes this system a promising
candidate in the topical treatment of aliments such as DED which require relatively rapid
drug release at the target site that is still sustained for a few hours. The release rate can be
tuned by varying the initial protein loading on the SiNPs or by silica surface modification
for other clinical applications. In contrast to the lysozyme-SiNP system where all the
adsorbed protein was released over time, only about half of the N-94 was released from
the N-94-SiNPs. N-94 is a much smaller and flexible molecule than lysozyme. This could
allow for more than one conformation of the adsorbed N-94. The relative stability of
these conformations could lead to the incomplete release observed. This could be a
concern that has to be addressed in the design and development of a N-94-SiNP treatment
system for DED. Nevertheless, the molecular integrity of N-94 was retained during the
release, as demonstrated by the MALDI results. Overall, the sustained delivery of N-94
can increase its bioavailability when applied to the cornea as compared to the current
drop treatment approach.
The SiNPs degradation was evident from the time dependent change of the particle
diameter. The degradation rate of SiNPs can been tuned to meet the requirements of a
particular delivery application. According to Yamada et al., in general, smaller sizes
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particles have higher degradation rates [49]. The ultimate dissolution time in vivo is
dependent on the particle size, synthesis method, and the properties of fluid it is subjected
to [49,50]. The degradation of the material is favorable for drug delivery application as
the carriers serve no other useful purposes after the therapeutics are delivered.
The clinical significance of the N-94-SiNP delivery system was supported by
experiments demonstrating that neat N-94 was non-toxic to HCECs and can effectively
reduce cell damage imparted by pro-inflammatory cytokines across a wide time and
concentration range (Figure 4.7 B). We found that release products from N-94-SiNPs
were non-cytotoxic, and N-94 released from SiNPs remained cytoprotective (Figure 8
and 9). We observed optimal cytoprotective effects at 10 nM and potentially 1 nM. This
corroborates existing lacritin studies that determined a 10 nM optimal concentration for
cytoprotective effects on HCECs and a 1–10 nM optimum for bactericidal activity
[29,30]. We applied N-94 for 16 and 20 hours to check cytoprotective effects over a long
period of cell stress and found that an exposure to 10 nM of N-94 for 20 hours was most
effective in our model. It is possible that the autophagy pathway that restores homeostasis
during inflammation was gradually triggered by increasing amounts of N-94 binding
syndecan-1 on the HCECs, reaching an optimum at 20 hours [29].
A limitation in the translatability of our study is the gap between the complete release of
N-94 from SiNPs after 8 hours and its optimal cytoprotective effects at 20 hours after
release. As mentioned, it may be worthwhile to study release kinetics in a solvent
containing tear proteins such as lacritin to possibly prolong release. Treating cells with
the conjugated N-94-SiNPs without first inducing release would also be useful in
studying optimal treatment durations once release kinetics are established in tearmimicking cell culture media. Future studies should also extend the study duration:
supplementing with additional N-94 daily as it is depleted can mimic daily drug
administration. In addition, other cell models could be explored to investigate the
preventative effect and rescue ability of N-94. More specifically, pre-treating HCECs
with N-94 before cytokine and post-treating insulted cells with N-94 could be employed.
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Trans-well inserts were used to separate N-94-SiNPs from HCECs to avoid the
endocytosis of SiNPs [17]. In clinical application, it must be ensured that the N-94-SiNPs
can remain on the ocular surface for the entire duration of N-94 release. This challenge
presents opportunities to create novel approaches for implementation. Future studies
could explore a secondary drug carrier for our proposed drug delivery system, such as
silicone hydrogel contact lenses. Embedding N-94-SiNPs into contact lens would further
ensure sustained drug delivery. While hydrogel contact lens itself can be considered as a
primary drug carrier, the SiNPs intermediate confers flexibility: it may be difficult to
synthesize different types of complex hydrogen matrices personalized for different
amounts of drug release, but we can more easily vary the amount of SiNPs embedded
into contact lenses for patients with varying degrees of dry eye.

4.5

Conclusions

As an excellent option for bioactive protein and peptide delivery, the SiNP-based
delivery system mediated the controlled release of cargo for a period of eight hours. This
type of release profile could be useful in dry eye treatment, as it could allow patients to
encounter the drug-elution at night, ideally while sleeping, and then to have 16 hours of
relief during waking hours. We have demonstrated that N-94 is functionally equipotent to
its parent protein lacritin and cytoprotective of stressed HCECs in its free dosage form.
The constitution of the N-94-SiNP delivery system successfully retained the peptide’s
molecular integrity and biological functionality. The peptide carrier was degradable and
was non-toxic to cells. The system has potential for incorporation into other ophthalmic
devices such as silicone hydrogel contact lens or new multifunctional devices. Overall,
the N-94-SiNPs delivery system represents a promising approach that can be further
developed for the treatment of DED.
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Chapter 5

5

Development of Multifunctional PVA-SiO2-IONP
Microparticles for TACE3
5.1

Introduction

Drug-eluting microparticles are characterized as matrix systems in which the drug is
homogeneously dispersed, either in dissolved or suspended form [1]. These micron-sized
delivery packages hold great utility in the clinical management of numerous diseases.
Plentiful microparticles composed of biocompatible polymers, such as chitosan, alginate,
poly(vinyl alcohol) (PVA) and poly(lactic-co-glycolic acid) (PLGA) were developed for
treating gastric diseases, lung cancer and hepatocellular carcinoma (HCC) [2–4]. Such
particles could be prepared via a wide array of processing techniques, including
microfluidics, electrospray and spray drying [1,5,6]. In addition to being used solely,
such particles can be used as a component in existing platforms, such as microfibers,
scaffolds, or bulk hydrogels for many applications, including drug delivery and tissue
regeneration [7–10].
Multifunctional drug-eluting microparticles have been a center of research in the past
decade. Such particles can fulfill two or more functions after administration, making
them promising in treating complex systems, such as tumors [11]. Targeted drug delivery
can localize the drug to the site of action, minimizing the unwanted toxicity to healthy
tissue [12]. Controlled release capability can avoid burst release and maintain an effective
drug concentration for a prolonged time [13,14]. Degradation of the delivery system is
beneficial as drug release can be modulated by the degradation rate of the carrier. In
addition, device removal is not required. Repeatable treatment is possible because the
carriers can be broken down into innocuous products and eliminated from the body after
the therapeutic is depleted [15]. Furthermore, imageable drug carriers facilitate the
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diagnosis and postoperative feedback, which is particularly advantageous in
interventional radiology for cancer treatment [16].
Composite hydrogels provide a powerful platform to construct multifunctional drugeluting systems. The idea behind it is to use nanoparticle fillers, biological factors, or a
combination of polymers to enhance and diversify the properties of traditional hydrogels
[17,18]. Poly(vinyl alcohol) (PVA) is one of the most commercially important
biocompatible polymers in use. PVA can be stabilized via physical crosslinking through
the freezing-thawing technique, in which no toxic chemical crosslinkers are required. The
porosity and mechanical properties can be altered by adjusting the process parameters,
polymer concentration in the solution and molecular weight of PVA [19]. The non-toxic
crosslinking approach, along with the tunable properties, renders PVA widespread
biomedical applications, including drug delivery, wound dressing and orthopedic
implants [20]. Iron oxide nanoparticles (IONPs) have gained particular interests due to
their excellent magnetic properties, making them good candidates as magnetic resonance
imaging (MRI) contrast agents and drug carriers for targeted delivery [21]. Furthermore,
the incorporation of IONPs into the PVA could endow the system with degradability.
Bannerman et al. introduced IONPs to the PVA hydrogels through in situ co-precipitation
[22]. IONPs were allowed to form hydrogen bonding with PVA chains and participate in
hydrogel crosslinking during the subsequent freezing-thawing cycles. As a result, the
gradual dissolution of IONPs in an acidic environment would weaken the linkages, and
therefore the stability of the matrix, leading to the ‘degradation’ of PVA. Silica (also
known as silicon dioxide, SiO2) has been "generally recognized as safe" by the FDA for
more than five decades and is widely used in the food industry as a color or formulation
stabilizer [23,24]. The presence of abundant surface silanols (Si-OH) allows the
conjugation to various organic functional groups, rendering silica nanoparticles (SiNPs)
with a wide range of applications in disease diagnosis and controlled drug release [25]. In
addition to SiNPs, silica-based materials in the form of composite hydrogels have
attracted significant attention. For example, silica-PVA hydrogels derived from acidcatalyzed sol-gel synthesis possess improved permeability and mechanical properties
compared to neat PVA hydrogels [26–28]. It is speculated that the relatively slow
hydrolysis step resulted in molecular chains contain sufficient silanol groups to
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participate in hydrogen bonding with the hydrogel polymers [29]. The formation of
silica-hydrogel interaction affects the intramolecular binding of the polymeric chains and
could reduce the crystallinity while improving the PVA's diffusivity [27,30]. This
improvement is particularly beneficial for drug delivery as it would facilitate the
permeation of drug molecules [31,32].
In this chapter, we continued the previous work on multifunctional PVA-IONP
microparticles (Chapter 3). However, we introduced silica to the composite hydrogel to
modify the loading and release ability of the delivery system. This material was prepared
via the acid-catalyzed sol-gel process and in situ co-precipitation. The microparticulate
PVA-SiO2-IONP system was fabricated by microfluidics and stabilized by the low
temperature thermal cycling (LTTC). The detailed scheme of the preparation of the
particles is presented in Figure 5.1. Various flow rates of the continuous phase and
dispersed phase were explored to make microparticles of adjustable sizes. The resulting
PVA-SiO2-IONP microparticles were comprehensively characterized in the aspects of
morphology, composition, magnetic properties, drug loading/release and degradation.
This multifunctional delivery system can potentially be used as drug-eluting
microparticles in different interventional radiology therapies, such as transarterial
chemoembolization (TACE) treatment of HCC.

135

Figure 5.1 Schematic illustration for the preparation of PVA-SiO2-IONP
microparticles.

5.2
5.2.1

Materials and Methods
Materials

PVA (MW 146,000-186,000, 99+% hydrolyzed), iron (III) chloride (FeCl3), iron (II)
chloride tetrahydrate (FeCl2•4H2O) were purchased from Sigma-Aldrich.
Tetraethylorthosilicate (TEOS, 99+%) was acquired from Alfa Aesar. Hydrochloric acid
(36.5%-38%, HCl) was obtained from Caledon. Sodium hydroxide (NaOH) pellets were
purchased from ThermoFisher Scientific. Doxorubicin hydrochloride was obtained from
Cayman Chemicals. Span80 was purchased from Fluka. Ethanol (95%) was acquired
from Commercial Alcohols. Phosphate buffer solution (pH 5.5) was prepared by a
procedure reported elsewhere [33]. All other chemicals were purchased from SigmaAldrich and were used without any purification.

5.2.2

Preparation of PVA Solution

A 2.99 wt% PVA solution was prepared at 90 °C under mechanical stirring (rpm 100).
The temperature was maintained for at least 3 h. The PVA was stored at room
temperature overnight to degas naturally.
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5.2.3

Preparation of Iron Chloride Solution

An iron chloride solution containing 20.66 wt% FeCl3 and 12.66 wt% FeCl2∙4H2O (2:1
molar ratio) in distilled water was prepared at room temperature.

5.2.4

Preparation of PVA-SiO2-Fe (II, III) Gel

First, a silica sol was prepared by slowly adding 2.76 mL TEOS into a solution
containing 2.7 mL of H2O, 2.95 mL of ethanol and 70 µL concentrated HCl. The
resulting mixture was maintained at 60 °C under magnetic stirring (rpm 150) for one
hour. To prepare the PVA-SiO2 gel, 1.36 g of silica sol was mixed with 13.64 g 2.99 wt%
PVA solution. The resultant gel was then aged at 60 °C under magnetic stirring (rpm
150) for five hours. The PVA-SiO2 gel, after cooling, was blended with 2.78 g iron
chloride solution. The resulting PVA-SiO2-Fe (II, III) gel was filtered through a 5 μm
filter (Acrodisc® syringe filter, Pall Laboratory) and stored at room temperature.

5.2.5

Fabrication of the Flow-focusing Microfluidic Device

A planar microfluidic system, comprising a flow-focusing configuration, was prepared
using poly(methyl methacrylate) (PMMA) slab (50 x 25 x 12 mm) by milling. The width
of the continuous phase and dispersed phase channels were 500 m and 200 m,
respectively. A second PMMA slab (50 x 25 x 12 mm) was sealed onto the channel slab
by screws. Two needles (20 gauge, Hamilton Company) attached with silicone tubes
(0.062 x 0.125’’, VWR International) were inserted into the inlet of the top slab to allow
independent injection of continuous phase and dispersed phase at selected rates
controlled by two syringe pumps (NE-1000, New Era Pump Systems Inc.). The droplets
generated were directed into a NaOH tank through an outlet tubing (0.023 x 0.038’’,
IntramedicTM PE tubing, BD).

5.2.6

Fabrication of PVA-SiO2-IONP Microparticles

Undecane containing 1 wt.% Span80 was used as the continuous phase, while the PVASiO2-Fe (II, III) gel was used as the dispersed phase. Microparticles were fabricated at
various flow conditions. The microfluidic fabrication was first conducted at a fixed
continuous phase flow rate (Qc=20 mL/h) while different dispersed phase flow rate
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(Qd=1-9 mL/h). Subsequently, the fabrication was conducted at two different Qd’s (Q d=1
mL/h and 3 mL/h) with various continuous phase flow rates (Qd=5-45 mL/h). The
produced droplets were collected in a reservoir containing 1.0 mol/L NaOH for
solidification. The resulting PVA-SiO2-IONP microparticles were collected and
thoroughly cleaned by 50 v/v% ethanol.
In later experiments (section 5.2.7-5.2.14), dispersed phase (Qd=3mL/h) was focused by
the continuous phase (Qc=20 mL/h). The droplets were guided into NaOH, collected and
washed as stated before. The cleaned microparticles were subsequently placed into a
programmed cryobath for three freeze-thaw cycles (FTCs) (from 20°C to -20°C then to
20°C at 0.1°C/min, held for one hour at the temperature limits). The microbeads were
stored in phosphate buffered saline (PBS) at room temperature until future use.

5.2.7

Drug Concentration Effect on DOX loading

Doxorubicin (DOX) was loaded into microparticles by immersion approach. Briefly,
0.25 mL microparticles were added into 1 mL of DOX stock solution of various
concentrations (C0=0.125 mg/mL, 0.25 mg/mL and 0.50 mg/mL) under mild shaking
condition overnight. Afterwards, the loading solution was retrieved and subject to UV-vis
measurements (Cary 60 UV-Vis, Agilent Technologies Inc.) at 485 nm. The drug-loaded
microbeads were carefully washed with PBS to remove the surface-associated DOX.
The loading capacity of doxorubicin was determined by Equation 1:
mg
Doxorubicin loading( ) = (W0 − Wt )/V b
mL

(1)

Loading efficiency was determined according to Equation 2:
Loading efficiency (%) =

(W0 −Wt)
W0

× 100%

where W0 is the initial amount of DOX in solution, Wt is the amount of DOX in the
supernatant, and Vb is the volume of hydrated PVA-SiO2-IONP beads in each sample.
Results were expressed as mean ± standard deviation (n=9).

(2)
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5.2.8

In vitro Release of DOX

The in vitro release profiles of DOX from PVA-SiO2-IONP microbeads were studied in
three release media at 37 °C with shaking at 110 rpm (shaking water bath, New
Brunswick Scientific). Microparticles with various DOX loading (i.e., C 0=0.125 mg/mL,
0.25 mg/mL and 0.50 mg/mL) were added into 15 mL corresponding release media (PBS
pH 7.4, phosphate buffer pH 5.5 and acidic water pH 5.5). At predetermined time
intervals, 1 mL of liquid was retrieved from each sample, and 1 mL of fresh media was
replenished. The DOX concentration in the liquid was quantified, as stated before.

5.2.9

Degradation of PVA-SiO2-IONP Microparticles

The degradation of microbeads was studied at 37 °C in PBS and phosphate buffer. In
detail, 0.25 mL blank PVA-SiO2-IONP microbeads were incubated with 15 mL
corresponding buffer. The degradation medium was replaced with a fresh one every 5
days. At designated time points, samples were retrieved and dried for microscopic
imaging.

5.2.10

Size Analysis

The size of microparticles was measured by an optical microscope (Olympus BX60)
coupled to an OMRX A35100U camera. Samples were prepared by dropping microbeads
suspension on the microscope glass slides. The sectional area of the beads was measured
manually using Image J software for over 100 samples and then converted into an
equivalent spherical diameter using Equation 3:
d = 2√A/π

(3)

where d is the equivalent spherical diameter and A is the measured sectional area of the
microbead. Results are expressed as the mean ± standard deviation of more than 100
particles in each sample.
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5.2.11

Scanning Electron Microscopy (SEM)/Energy-Dispersive Xray (EDX)

Samples were critical point dried (K850 Critical Point Dryer, Electron Microscopy
Sciences) and fixed on a carbon tape. A layer of 5 nm osmium coating was sputtered onto
the surface of the samples using a plasma coater (OPC80T, Filgen) before imaging.
Scanning electron micrographs and elemental mapping were obtained using an SEM
coupled with energy EDX spectroscopy (LEO (Zeiss) 1540XB FIB/SEM).

5.2.12

Transmission Electron Microscopy (TEM)

To visualize the silica particles, silica sol was properly diluted using water, sonicated and
dripped onto a Formvar carbon-coated 400 mesh copper grid (Electron Microscopy
Sciences), air-dried and observed under TEM (CM10, Philips).
The internal structure of PVA-SiO2-IONP microbeads was analyzed using TEM. Samples
were dehydrated in acetone and embedded in epoxy resin. After that, embedded beads
were ultramicrotomed (Reichert-Jung Ultracut E) with a diamond knife and the resulting
slices were placed on copper grids (Electron Microscopy Sciences) for imaging at 80 kV.

5.2.13

Fourier Transform Infrared Spectroscopy (FTIR)

The samples of neat PVA, PVA-SiO2 gel and PVA-SiO2-IONP microparticles were dried
in an oven at 60 °C overnight. FTIR analysis (Perkin-Elmer, Massachusetts, USA) was
then performed in the region of 4000-500 cm-1 at a resolution of 2 cm-1.

5.2.14

Vibrating Sample Magnetometry (VSM)

PVA-SiO2-IONP microparticles were oven-dried at 60 °C overnight. The magnetization
curve of the microparticles was obtained using a vibrating sample magnetometer
(LakeShore 7407, Lake-ShoreCryotronics Inc.) at 298 K.

5.2.15

Statistical Analysis

For DOX loading and release experiments, a sample size of three or nine was used for
each condition. For degradation study, a sample size of three was used for each buffer
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condition. Statistical analysis was performed using Microsoft Excel and GraphPad Prism
v9 (La Jolla, CA). Results are reported as the mean ± standard deviation.

5.3
5.3.1

Results
Microfluidic Fabrication of Size-tunable PVA-SiO2-IONP
Microparticles

The flow-focusing microfluidic device was effective in producing tadpole-shaped PVASiO2-IONP microbeads with tunable sizes (129-272 𝜇m). The polydispersity index (PDI),
defined as the ratio between the standard deviation and the mean diameter of particles
multiplied by 100, was calculated for each flow condition. The droplets developed PDI
values ~10%, suggesting that a reasonably monodisperse population [34,35].

Figure 5.2 Relationship between particle diameter and flow rates. (A) Diameter as a
function of dispersed phase, Qc=20 mL/h, Qd=1-9 mL/h. (B) Diameter as a function
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of continuous phase, Qd=1 mL/h, 3 mL/h, Qc=5-45 mL/h. (C)-(E): Optical
microscope images and size distributions of microbeads fabricated under different
flow rate conditions. For a fixed Qc=20 mL/h, the particle size decreased first and
then increased as the Qd increased. At a fixed Qd, the particle size decreased with an
increased Qc.

5.3.2

Characterization of PVA-SiO2-IONP Microparticles

The morphology of PVA-SiO2-IONP microbeads was shown in Figure 5.3 A. The EDX
analysis (Figure 5.3 D) confirmed the co-existence of iron oxide and silica throughout the
microparticles.
(B)

(A)

(D)

(C)

(E)

Figure 5.3 (A) and (B): surface morphology of microparticles (Qd=3 mL/h, Qc=20
mL/h). (C) and (D): EDX spectrum of microparticles with a square indicating the
area of analysis. (E) is the EDX elemental mapping of the entire sample in (C). The
EDX analysis confirmed the presence of iron and silica content in the PVA-SiO2IONP microparticles.
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The silica and iron oxide components were visualized by TEM (Figure 5.4). Silica
microparticles were found in a spherical shape with a diameter of 1.3 ± 0.5 𝜇m. IONPs
were well dispersed in the PVA matrix. The diameter of IONPs was measured to be 2.3
± 0.8 nm.

Figure 5.4 TEM images of (A) silica sol and (B) PVA-SiO2-IONP microbeads. Acidcatalyzed sol-gel process contributed to spherical silica microparticles with a
diameter of 1.3 ± 0.5 𝝁m. IONPs were 2.3 ± 0.8 nm in diameter and were welldispersed in the microbeads. Due to the large variance of the dimension of silica
microparticles and IONPs, individual silica microparticle cannot be displayed in (B)
with IONPs.
The FTIR spectrum of neat PVA, PVA-SiO2 gel, PVA-SiO2-IONP microparticles were
shown in Figure 5.5. The neat PVA sample showed characteristic bands at 3220 cm-1,
2897 cm-1 and 1078 cm-1 due to the O-H stretching, C-H stretching, and C-O-C,
respectively [36].
The PVA-SiO2 composite gels showed a new band at 946 cm-1, attributed to the Si-OH
stretching [37]. The spectra in the range of 1040-1100 cm-1 indicated the co-existence of
C-O-C, Si-O-Si and C-O-Si stretching [36,37]. The increase in the width of the peaks and
its slight shift towards a lower wavenumber could be associated with the formation of SiO-Si groups (~1060 cm-1) and intermolecular reaction between TEOS and PVA (C-O-Si
stretching, 1080-1120 cm-1) [37,38]. This hypothesis was supported by the considerable
reduction of the intensity of the O-H band (3220 cm-1), which might be attributed to a
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condensation reaction between the hydroxyl groups from silicate (i.e., silanol groups) and
PVA [39]. Compared with the O-H bands (3220 cm-1) of PVA and PVA-SiO2 gels, an
increase in the width of O-H band after IONPs incorporation was observed for PVASiO2-IONP beads, indicating a possible formation of intermolecular bonding between the
IONPs and PVA through hydroxyl groups.

Figure 5.5 FTIR spectra of neat PVA, PVA-SiO2 gel, and PVA-SiO2-IONP
microbeads. The emergence of C-O-Si peak and reduction of O-H peak indicates the
condensation reaction between -OH groups of PVA and surface silanols of silica.
To characterize the magnetic properties of the delivery system, VSM was performed on
the PVA-SiO2-IONP microparticle sample. The magnetization curve (Figure 5.6 A)
revealed the paramagnetic nature of the microparticles.
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(A)

(B)

Figure 5.6 Magnetization curve of PVA-SiO2-IONP microparticles. The
microparticles exhibited paramagnetic behavior. (B) Microparticles dispersed in
PBS attracted by a permanent magnet.

5.3.3

Drug Concentration Effect on DOX Loading

PVA-SiO2-IONP microparticles were incubated with DOX solution of 0.125 mg/mL,
0.25 mg/mL and 0.50 mg/mL, the results of drug loading were summarized in Table 5.1.
A higher loading while lower entrapment efficiency was observed when a more
concentrated DOX stock solution was used. The DOX loading was 0.45 ± 0.03,
0.79 ± 0.08 and 1.34 ± 0.09 mg/mL, respectively. Under these loading conditions, the
entrapment efficiency was 89.8 ± 6.6%, 79.3 ± 7.9% and 66.9 ± 4.5%, respectively.
Table 5.1 Drug concentration effect on DOX loading.

5.3.4

In vitro Release of DOX

Figure 5.7 shows the release profile of PVA-SiO2-IONP microparticles with various
DOX loading (i.e., 0.45 ± 0.03, 0.79 ± 0.08 and 1.34 ± 0.09 mg/mL) in different
release buffers. The drug release was fast on the first day and sustained release was
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observed afterwards. The release plateau was reached at 7 days for all subgroups. Within
the same DOX loading group, the release rate increased with a higher ionic concentration
in buffer or a lower pH value.
The loading effect on DOX release was illustrated in Figure 5.7 D. PVA-SiO2-IONP
microspheres with a higher loading rendered a slower release. At day 21, the cumulative
release for microspheres with 0.45 ± 0.03, 0.79 ± 0.08 and 1.34 ± 0.09 mg/mL loading
were 44.94 ± 0.88%, 45.33 ± 2.82% and 33.50 ± 1.62%, respectively.
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Figure 5.7 In vitro drug release from DOX-loaded PVA-SiO2-IONP microparticles:
(A)-(C) effect of release conditions on DOX release; (B) effect of drug loading on
DOX release. Within the same DOX loading subgroup, the release rate increased
with a higher ionic concentration in buffer or a lower pH value. At the same buffer
condition, microparticles with a higher DOX loading contributed to a slower and
lower percentage of release.

5.3.5

Degradation of Microparticles

The degradation of microparticles was evidenced by the morphological change during the
test period (Figure 5.8). PVA-SiO2-IONP microbeads degraded faster in acidic phosphate
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buffer than in PBS, as the uneven surface and deformation of the original tadpole shape
were more apparent from SEM images.
Buffer
Condition

Time (day)
0

14

35

56

PBS (pH 7.4)

Phosphate
buffer (pH 5.5)

Figure 5.8 SEM images of the PVA-SiO2-IONP microparticles at two buffer
conditions. Pictures were obtained after 0, 14, 35 and 56 days’ immersion in the
corresponding buffer. Error bar: 20 𝝁m, except for day 14 PBS (error bar 100 𝝁m).
The degradation of microparticles at both buffer conditions was evidenced by the
morphological change during the test period.

5.4
5.4.1

Discussion
Microfluidic Fabrication of Size-tunable PVA-SiO2-IONP
Microparticles

During the microfluidic fabrication process, a dispersed fluid composed of PVA, SiO 2
and iron oxide precursors was sheared by the two continuous oil streams at the junctions
of three microfluidic channels to form droplets. The resulting droplets were directed into
the NaOH bath, where ferric and ferrous iron salts co-precipitate to form magnetite
(Fe3O4) nanoparticles. The co-precipitation reaction can be represented by:
2Fe3+ + Fe2+ + 8OH − = 2Fe(OH)3 Fe(OH)2 → Fe3 O4 + 4H2 O

(4)
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The flow rate of the dispersed phase and continuous phase are important parameters in
determining the diameter of the microbeads. The size of the droplets decreased with an
increased Qc at a fixed Qd, which was consistent with the literature [283,297]. It has been
reported that within a certain Qc range, a greater Qc value would result in more rapid
thread collapse and the breakup of the dispersed phase, leading to a reduced particle size
[42]. The literature also suggests that the increase in Qd will increase the size of
microparticles [40], which was partially contradicted to our results, where the particle
diameter first decreased with a larger Qd. When Qd exceeded the threshold value (i.e., 3
mL/h), larger microparticles with broader size deviation were generated. The initial
downward trend could be resulted from the instability of droplet breakup at the early
operating conditions or the transition of breakup pattern (e.g., from dripping to jetting)
[43]. However, the droplet generation process must be microscopically examined along
with the computation of relevant parameters (i.e., capillary number and Weber number)
to fully understand fluid mechanics and the effect of flow rates on the size of final
droplets [42,44].
The tadpole shape of PVA-SiO2-IONP microparticles could be attributed by the
solidification process that emerged at the oil phase/NaOH interface. In the NaOH
collection bath, the continuous phase (i.e., oil phase) would form a separate layer on the
top of the NaOH phase with extended fabrication time. It was speculated that during the
slow passage of PVA-SiO2-Fe (II, III) droplets through the oil phase/NaOH interface, the
droplets deformed into tail shape due to the combined effect of gravity, interfacial
tension, impact and tangential stress [45,46]. The co-precipitation of iron precursors
proceeds in the presence of PVA and gradually increased the rigidity of microgel, which
would prevent further changes in particle morphology. Indeed, non-spherical hydrogel
microparticles are expected in droplet generation with a subsequent “external gelation”
procedure. Alginate microparticles with different tailed morphologies have been
intentionally produced by changing the viscosity of the polymer solution, the
concentration of the crosslinker and collecting distance [47,48].
Monodisperse, size-controlled and tail-shaped PVA-SiO2-IONP microparticles are
attractive as drug-eluting microparticles for TACE. The uniform morphology could
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facilitate the catheter delivery, which could potentially avoid the off-target embolization
and allow a more proximal occlusion [49,50]. The non-spherical microparticles render a
higher surface area compared to spherical ones, which makes faster drug release possible
[48].

5.4.2

Characterization of PVA-SiO2-IONP Microparticles

Silica microparticles were formed in the acid-catalyzed sol-gel process. The reaction is
generally carried out through simultaneous or successive reactions of hydrolysis and
polycondensation of silica precursors in the presence of an organic cosolvent [29]. The
net reactions can be described by:
Hydrolysis: ≡Si-OR + H2O ⇌ ≡Si-OH + R-OH

(5)

Polycondensation: ≡Si-OH + HO-Si≡ ⇌ ≡Si-O-Si≡ + H2O

(6)

The size of generated silica particles was found to be similar to what was developed
using the acidic catalysis procedure [51] but much larger than the particles derived from
basic conditions [52]. The large diameter and broad size distribution can be explained by
the gel formation scheme. In an acid-catalyzed sol-gel procedure, the hydrolysis rate is
greater than the condensation rate. The silica tends to form linear polymeric networks that
are occasionally crosslinked. In contrast, hydrolysis is a lot faster than condensation
under basic conditions, which results in uniform and discrete silica particles [29].
The incorporation of silica into the PVA is beneficial as it can potentially improve the
drug loading and release capability of the delivery system. In a hydrogel-based delivery
system, the microscopic structure of the polymeric network governs inward and outward
molecular diffusion [53]. It was believed that the crystalline regions of polymers are
impermeable to solutes [30,31]. This was supported by the reduction in diffusion
coefficients through PVA gels with a greater degree of crystallinity or denser polymeric
network. Moreover, PVA with a denser network has stronger intermolecular interactions
displays a smaller degree of swelling and, therefore pore expansion. This was believed to
hinder drug penetration and release from the PVA matrix. The incorporation of silica
components could reduce the density of polymer mesh and the degree of crystallinity,
therefore improve the permeation of drug molecules [54–56]. It was evidenced that the
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incorporation of silica nanoparticles (SiNPs) can interact with -OH groups from PVA and
interfere with the PVA chain arrangement, which would diminish the crystallinity of
PVA and contribute to an improved solute permeability [26–28].
TEM micrographs confirmed the formation of well-dispersed and relatively uniform
IONPs (D=2.3 ± 0.8 nm). The ultrasmall size (<50 nm) and good dispersity could be
attributed by the protective effect of PVA [57]. In a study conducted by Lee et al., IONPs
of average diameter 4-7 nm were synthesized via in situ co-precipitation. The ferric and
ferrous ions co-precipitate in the PVA solution, during which PVA irreversibly adsorbed
on the surface of IONPs [58]. It was hypothesized that the interaction of PVA hydroxyl
groups with IONPs could protect the nanoparticles from growth and aggregation through
steric stabilization [59,60].
The formation of IONPs within the microparticles is desirable for their applications as
DEBs. First, IONPs could contribute to the crosslinking of the hydrogel and allow the
delivery system to ‘degrade’ [22]. IONPs could provide contrast enhancement to
magnetic resonance (MR) images [61]. More importantly, the co-localization of the
contrast agent with drug contributes to more definitive and precise location of the drug,
which could be useful for intraprocedural guidance and post-operative assessment.
Moreover, the IONPs endow the microparticles with magnetic properties, making them
promising in magnetically-guided drug delivery [62].
The PVA-SiO2 interaction was revealed by the FTIR spectrum. Through the acidic
hydrolysis of TEOS in the presence of PVA, the silanol groups not only condense with
each other but also react with the hydroxyl groups of PVA to form C-O-Si bonds
[26,39,63]. This PVA-SiO2 interaction could be desirable as it would affect the overall
crosslinking of the hydrogel and render a more drug-permeable matrix. The contribution
of SiO2 to the PVA crosslinking should also be considered for the degradation process.
Compared with the O-H peak of PVA-SiO2 samples, the PVA-SiO2-IONP gave a peak
with a weaker intensity and broader width. This could be attributed by the consumption
of -OH groups during the crosslinking between PVA and IONPs [22]. Furthermore, a
significant reduction of the peak in the range of 1040-1100 cm-1 was observed. The
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variation in this peak was consistent with the decrease in the concentration of PVA, SiO 2
in the PVA-SiO2-IONP formulation, as compared to neat PVA and PVA-SiO2 gels. This
could also be an indication that the complex interactions among PVA, SiO 2 and IONP
have weakened certain interactions.
The near-linear magnetization curve implied the paramagnetic property of the PVA-SiO2IONP microparticles, which was commonly found in FeO and Fe2O3 [64–66]. The
formation of non-magnetite impurities could be due to the presence of oxygen and/or the
unconfined stoichiometric and pH condition [67]. In a co-precipitation reaction,
stoichiometry and pH are crucial to ensure the formation of Fe3O4 nanoparticles. The
ideal ratio of Fe2+/ Fe3+ is approximately 0.5, while the optimal pH window remains 8.510 [68,69]. The presence of oxygen and strong alkaline solutions could induce the
oxidation of Fe2+ ions to Fe3+ ions, making the effective Fe2+/Fe3+ < 0.5 [67]. In the
context of the pH effect, re-dissolutions of Fe(OH)3 and Fe(OH)2 begin at pH >11, which
could change the composition of formed IONPs [70]. To ensure the formation of Fe3O4
nanoparticles, excess Fe2+ ions (e.g., Fe2+: Fe3+=2:3) could be used. An alternative
approach would be to employ argon or nitrogen to eliminate the oxygen in the system
[71]. Nevertheless, PVA-SiO2-IONP microparticles demonstrated magnetic response and
zero residual magnetization was produced. This suggests that these microparticles do not
retain any magnetization after the external magnetic field is removed, which can
potentially avoid the particle agglomeration in vivo [72]. Magnetic PVA-SiO2-IONP
microparticles may find their application in MRI contrast enhancement and magnetic
targeting.

5.4.3

Drug Concentration Effect on DOX Loading

PVA-SiO2-IONP microparticles could achieve a greater DOX loading and lower
entrapment efficiency at a higher initial DOX concentration. This phenomenon could be
attributed to the finite number of binding sites when the amount of microparticles was
fixed. Moreover, the increase in loading (in percentile) was smaller than in the DOX
concentration, indicating a longer incubation time might be necessary. The competition
between DOX molecules would need a longer time to reach equilibrium.
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5.4.4

In vitro Release of DOX

The effect of ionic concentration and pH on DOX elution was shown in Figure 7 A-C. At
all loading levels, DOX release was faster in pH 5.5 phosphate buffer than in the H 2O of
the same pH, indicating the presence of ions in elution medium can accelerate the release.
Acidic phosphate buffer rendered faster release compared with saline. As the ionic
concentration and pH were different for the two buffers, it is challenging to claim the pH
effect on DOX release. However, we believe that an acidic pH plays an essential role in
DOX release. DOX is an amphoteric drug that presents predominantly in its cationic form
[73]. It contains deprotonable phenolic groups (-OH, pKa 9.5) and a protonable amine
group (-NH2, pKa 8.2) [74]. Yang et al. assembled a DOX-loaded delivery system using
graphene oxide. DOX elution profile was studied at three pHs (2, 7 and 10), and the
acidic pH environment provided the fastest and greatest release. It was hypothesized that
the DOX interacted with the carrier through the hydrogen bonding between the -OH
groups on the graphene sheet with the -OH and -NH2 groups in DOX. In an acidic
environment, the protonation of amine groups accelerates the DOX release by reducing
the number of functional groups available for hydrogen bonding [75]. Such pHdependent release is particularly attractive for drug delivery applications. It can
potentially allow tumor-specific release, because the pH value in tumor tissue (pH 6.56.8) is different from healthy tissue (pH 7.35-7.45) [76].
As shown in Figure 7 D, PVA-SiO2-IONP microparticles with a higher loading provide a
slower DOX release. This could be explained by the increased hydrophobicity of the
microparticles after loading. It was found that the DOX molecules could introduce π − π
drug-drug interactions, which increased the hydrophobicity of the drug carriers [4]. As
such, microparticles with greater DOX loading became more hydrophobic than those
with lower loading. As a consequence, the water penetration hence drug diffusion would
be retarded, resulting in a slower drug release [77].
For all subgroups, an incomplete drug release was observed, which could possibly be
explained by the entrapment of DOX in the hydrogel matrix and/or the adsorption of
DOX to the surface of the glass vials [78,79]. The plateau phase in DOX release could be
followed by a sustained but slow release of the rest of the payload as the degradation
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progresses. Future study could be conducted for an extended period of time to fully
reveal the drug release profile. Nevertheless, the release was sustained for 7 days, and the
release rate was adjustable by altering the DOX loading. Such release profile could be
engineered to comply with the frequency of TACE treatments and provide a better tumor
response due to the prolonged drug release [16].

5.4.5

Degradation of Microparticles

It has been hypothesized that the degradation of microbeads was contributed by the iron
dissolution and PVA matrix disintegration (Chapter 3). This study provides additional
quantitative data to support the hypothesis. However, we are not able to conclude the
degradation mechanism of PVA-SiO2-IONP microbeads because the impact of silica
dissolution on degradation is yet to be elucidated. Future studies on sample weight loss,
thermal properties, compositional analysis of the degradation medium are required to
understand the degradation process fully. The degradation data should also be compared
with DOX release profile to better understand the role of carrier degradation in drug
release.

5.5

Conclusion

Multifunctional microparticles were successfully prepared from poly(vinyl alcohol),
silica and iron oxide via sol-gel synthesis, in situ co-precipitation and microfluidics. The
size of the microparticles was tunable by adjusting the flow rate of the continuous phase
and dispersed phase. The PVA-SiO2-IONP microparticles were able to load DOX and
provide a controlled release for 7 days. This could be followed by a sustained but slow
release of the rest of the payload as the degradation progresses. The release profile was
adjustable by altering the drug loading. It was speculated that the DOX release from the
system was co-dependent on the ionic concentration and pH of the release medium.
Furthermore, the microparticles were subject to degradation in physiological conditions.
Taken together, multifunctional PVA-SiO2-IONP microparticles can be potentially used
as drug-eluting agents for locoregional therapy, such as transarterial chemoembolization
and wound healing. Further research in the PVA-silica interaction and microparticle
degradation is required to comprehensively evaluate this drug delivery system.
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Chapter 6

6

Conclusion and Recommendations

6.1 Summary and Conclusion
The overall objectives of this thesis are to develop multifunctional drug delivery systems
for locoregional therapy (Figure 6.1). Nano- and microparticulate systems were prepared
using organic or inorganic biomaterials. These delivery systems were characterized in
their composition, morphology, drug loading/release and degradation. The results
demonstrated sustained drug release capacity and in vitro degradability. The summary of
each delivery system is presented below.

Figure 6.1 Schematic of the research work described in Chapter 3-5.
In Chapter 3, multifunctional PVA-IONP microparticles were developed as DEBs for
TACE treatment. The superparamagnetic IONPs were entrapped in the PVA matrix
through in situ coprecipitation and freezing-thawing cycles. Droplet microfluidics was
employed to fabricate microparticles. The resulting beads were in a teardrop shape with a
relatively narrow size distribution. PVA-IONP microbeads have demonstrated multiple
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functionalities relevant to the application as DEBs, including targetability, detectability,
controlled DOX release and degradation. The highlights of this project are:
1. Targetability. PVA-IONP microparticles were superparamagnetic and can be
attracted by a permanent magnet.
2. Imageability/Detectability. Microparticles were effective in producing a contrast
enhancing effect on T2-weighted MRI images.
3. DOX loading and release. PVA-IONP microparticles provided a DOX loading of
0.49 ± 0.02 mg/mL. The release was in a sustained manner during the course of
one week.
4. Degradability. The degradation of the microbeads was in the form of iron release
and PVA matrix disintegration.
5. Co-localization of contrast agent with DOX. This would about a precise location
of the carrier and drug in relevance to tumor site.
Chapter 4 described the development of bioactive proteins and peptides delivery system
using non-porous SiNPs. The system was first assembled using lysozyme as the model
protein. The adsorption kinetics and isotherm were studied to reveal the loading
mechanism. Protein release and the dissolution of SiNPs in PBS were investigated. The
SiNPs were then loaded with N-94, the peptide derived from a tear glycoprotein, lacritin,
that is effective in dry eye treatment. The SiNP system is attractive as a drug delivery
formulation for treating dry eye disease.
The highlights of this work are shown below:
1. Protein loading is driven by chemisorption and will form a monolayer on SiNP
surface at low protein concentration. As such, it is expected to be a maximum
loading capacity determined by the number of binding sites and hindrance effect.
2. SiNPs can provide a controlled release for proteins and peptides for 8 hours.
3. The nanocarriers can protect molecular integrity and biofunctions of the peptides.
4. SiNPs are dissolvable in PBS. The dissolution is time-dependent and results in
reduced particle size and a porous structure.
5. N-94 is functionally equipotent to its parent protein, lacritin.
6. SiNPs are non-toxic to cells.
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Chapter 5 introduced the development of PVA-SiO2-IONP system, which gives improved
performance over the PVA-IONP microparticles in terms of increased loading capacity
and tunable drug release. The multifunctional PVA-SiO2-IONP beads were in a tadpole
shape and developed a paramagnetic response. SiO2 microparticles participated in the
hydrogen bonding with PVA and improved the loading and release capacity of the
delivery system. These microparticles are attractive as DEBs for locoregional treatment
of diseases. The highlights of this work are listed below:
1. The size of the microparticle could be tuned by varying the flow rates of the
continuous and dispersed phase.
2. PVA-SiO2-IONP microparticles rendered a 61.2% increase in DOX loading
capacity compared with the original system.
3. PVA-SiO2-IONP microparticles can provide a controlled release of DOX for 7
days. The release profile is tunable by varying the drug loading.
4. DOX release is dependent on the pH and ionic concentration of the release media.
A more acidic pH and higher ion concentration would contribute to a faster and
greater drug release.

6.2

Significance of Research

This thesis explored the development of nanoscopic and microscopic drug delivery
systems. In Chapter 3 and Chapter 5, chemical (e.g., coprecipitation and sol-gel process)
and physical routes (e.g., freezing-thawing cycling) were employed to prepare
multifunctional drug carriers. Material processing techniques such as droplet microfluidic
demonstrated efficiency and stability in producing hydrogel microparticles. The resulting
particles exhibited the integration of several desirable properties, including targetability,
visibility/detectability, co-localization of contrast agent with drug, sustained drug release
and degradation. The robust and scalable microfluidic fabrication of microparticles would
aid the success of clinical translation. The physical crosslinking method allows the
stabilization of the hydrogel without using toxic crosslinkers, which would make the
resulting system advantageous for in vivo applications. The resulting multifunctional
delivery platform holds the promise to address the limitations of current DEBs, which
would ultimately lead to improved efficacy and safety of TACE treatments.
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In Chapter 4, a simple drug nanocarrier composed of SiNPs was developed using Stöber
synthesis. The protein adsorption kinetics and isotherms were studied to reveal the
loading mechanism. The adsorption pattern is helpful in determining, altering the loading
and regulating the protein release. The SiNPs are effective in protecting molecular
integrity and biofunction of protein therapeutics during release. The SiNP-protein system
is a proof-of-concept design towards many applications for ocular drug delivery.
In summary, my Ph.D. work involved significant research work in the design, synthesis,
and processing of multifunctional materials for drug delivery applications. The choice of
materials and fabrication techniques would guide future work in developing novel
delivery systems. The delivery formulations we developed could be used as drug carriers
alone. The primary application would be in TACE-HCC treatment. Other potential
applications include TACE therapy for colorectal liver metastases and hyperthermia
treatment for brain tumor. The application could be further expanded if they were
combined with other delivery platforms, such as microfibers, scaffolds and contact lens to
serve as drug-eluting medical devices.

6.3

Future Studies

Based on the length scale of the delivery system we designed, this thesis could be
aggregated into two main projects. Chapter 3 and Chapter 5 described the development of
multifunctional ‘nano-on-micro’ microparticles. Chapter 4 involved work on the
development of silica-based nanocarriers for protein delivery. Future studies will be
discussed for Chapter 3 and 5 together, and separately for Chapter 4, due to the similarity
of the work.
Development of multifunctional hydrogel microparticles (Chapter 3 and Chapter 5)
The co-flow or three-dimensional (3D) flow-focusing microcapillary devices should be
explored to produce the microparticles [1]. This architecture would allow a better sealing
than quasi-2D planar devices, which is expected to secure the driving force (i.e., the
relative pressure difference between the inlet and outlet of the microfluidic channel) in
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robustly delivering the fluids [2]. In addition, a 3D geometry would circumvent the
unstable breakup of droplets, as the fluids do not contact the walls [3].
To examine the targetability of the multifunctional ‘nano-on-micro’ microparticles, MR
steering could be tested in bifurcated fluidic tubing using a clinical MRI scanner [4]. The
distribution of particles should be recorded to evaluate the spatial control of system.
Steering ratio and mass loss can be quantified to assess the sensitivity and reliability of
this approach.
In the degradation study, additional quantitative and qualitative experiments could be
conducted. Size exclusion chromatography (SEC) can be employed to examine the
microbeads. Changes in molecular weight and molecular weight distribution could
indicate the degradation of PVA [5]. Differential scanning calorimetry (DSC) could be
performed to monitor the changes in glass transition temperature during the degradation.
Dynamic light scattering (DLS) can be utilized to measure the size reduction caused by
the disintegration of the matrix. Moreover, the degradation could be quantified
gravimetrically.
Future work should also be dedicated to revealing the biocompatibility and efficacy of
the drug eluting microparticles. For biocompatibility study, normal cells (e.g., epithelial
cells) could be incubated with drug-free microparticles. Cell apoptosis should be
analyzed by flow cytometry. To study the efficacy of the delivery system, cancer cells
(e.g., HepG2 cells) could be treated with drug-loaded particles. The antitumor effect of
the system against HepG2 cells could be evaluated using a methyl thiazolyl tetrazolium
(MTT) assay. Morphological changes of cells in response to the treatments will be
microscopically examined to reveal the apoptosis pathway [6].
To explore the full application spectrum of our multifunctional delivery systems, studies
on drug release and heating effect could be conducted with the presence of an alternating
magnetic field (AMF). This would allow the assessment of their clinical applicability in
magnetic-responsive drug release and magnetic hyperthermia cancer therapy [7].
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Development of silica nanocarriers for bioactive protein delivery (Chapter 4)
This study demonstrated the feasibility of using SiNPs as protein carriers. Future work
should focus on improving the loading capacity and demonstrating the superiority of the
drug delivery systems over free drugs. In detail, porous SiNPs could be synthesized to
improve the loading capacity. Alternatively, non-porous SiNPs could be functionalized to
introduce more surface binding sites. A cell study could be performed to examine the
effectiveness of delivery systems. Stressed corneal cells could be treated with free
bioactive proteins and SiNP-protein systems separately. A comparative study on cell
viability and metabolism should be performed.
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Appendices
Appendix A: PVA-IONP microbeads size measurement

Equivalent spherical diameter is calculated using the following equation:
𝑑 = 2√𝐴/𝜋
where d is the equivalent spherical diameter, while A is the measured sectional area of a
microbead.
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Appendix B: Preparation of pH 5.5 phosphate buffer
Solution I: dissolve 13.61 g of potassium dihydrogen phosphate (KH2PO4) in distilled
water and dilute to 1000 mL.
Solution II: Dissolve 35.81 g of disodium hydrogen phosphate (Na2HPO4) in distilled
water and dilute to 1000 mL.
Mix 96.4 mL of solution I and 3.6 mL of solution II.
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Appendix C: Calibration curve for doxorubicin at 485 nm
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Appendix D: Fitting parameters and curves for lysozyme adsorption kinetics and
isotherms
Adsorption kinetics:
Pseudo-first order
𝑙𝑜𝑔10(𝑄𝑒 − 𝑄𝑡 ) = 𝑙𝑜𝑔10 𝑄𝑒 − 𝑘1 𝑡
Pseudo-second order
𝑡
1
𝑡
=
+
𝑄𝑡 𝑘2 𝑄𝑒2 𝑄𝑒

Dynamic
Model

Pseudo-First Order

Pseudo-Second Order

Qe
(mg/g)

k1 (h-1)

R2

Qe
(mg/g)

k2 (g mg-1h-1)

R2

17.77

0.016

0.90

34.97

0.012

>0.99

Table S1 Pseudo-first-order, pseudo-second-order parameters for lysozyme adsorption.
Adsorption isotherms:
Langmuir isotherm
𝐶𝑒
1
1
=
𝐶𝑒 +
𝑄𝑒 𝑄𝑚
𝑄𝑚 𝑏
Freundlich isotherm
log10 𝑄𝑒 =

1
log10 𝐶𝑒 + log10 𝐾𝐹
𝑛

Redlich-Peterson isotherm
𝑄𝑒 =

𝐾𝑅 𝐶𝑒
𝛽

1 + 𝛼𝑅 𝐶𝑒
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Table S2 Fitting parameters for Freundlich, Langmuir and Redlich-Peterson isotherms.

80
70

Qe (mg/g)

60
50
40
30

Experimental
Freundlich
Langmuir
Redlich-Peterson

20
10
0
0

500

1000

1500

2000

Ce (mg/L)

Figure S1 Comparison between the measured and modelled equilibrium isotherm profile.
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